The 7th International Congress of Immunology will be held in the city of Berlin (West) on 30 July -5 August, 1989 and is being organized by the Gesellschaft f0r Immunologie. Based on estimates from the number of submitted abstracts, between 7000 and 8000 immunologists are expected to attend. This amounts to approximately one third of the total membership of the 39 national societies that constitute the International Union of Immunological Societies (IUIS). The burden of organizing such a conference is more than fully compensated for by the overwhelming worldwide interest.
The congress is being held under the auspices of the IUIS which was founded in 1969 by ten national immunological societies including the Gesellschaft f0r Immunologie. The IUIS has grown rapidly to its present size and strength. Without the IUIS and the scientists who d~vote much of their time and effort to this organization, it would not be possible to have an international congress such as this.
Germany and the city of Berlin have a great past in immunology. One hundred years ago, antibodies were first discovered here by Emil von Behring and his Japanese colleague S. Kitasato. Names such as Robert Koch, Rodolf Virchow and Paul Ehrlich need no special explanations. Today, immunologists in Germany are proud to have been entrusted, by the international corn-
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Klaus Eichmann rnunity of immunologists, with the organization of its principal and most comprehensive meeting. During the conference, we shall honor the great past of immunology in Germany with a historical exhibition. For the scientific program, the unanimous opinion of the Organizing Committee was to avoid ary sort of nationai representation but Lo ask the very best in the international commur..ty to serve as chairpersons and speakers. Immunology as it stands in present day Germany is r~vlewed in this issue of Immunology Today.
No other scientific discipline has contributed quite as much in recent years as immunology has to both basic biology and its application in medicine. Our knowledge of the biology of genes and their products, of cells and multicellular organisms and also our diagnostic and therapeutic skills in practical medicine have been greatly furthered by information drawn from immunological research. Immunology has also become more heterogeneo,-s than perhaps any other scientific discipline. No contemporary immunologist can claim to have a comprehensive understanding of his entire field. Faced with this situation -which has both merits and difficulties -the International Congress of Immunology provides a singular opportunity for the individual scientist to recognize the major avenues of immunological research and thus to define individual pathways. More than ever before do we need this forum of mutual information and learning.
Immunology T~day, VoL 10, No. 8, 1989 Supplement The immune system must certainly be one of the most intensively studied parts of the body. It is estimated that cver 100 000 scientists all over the world work in the many different areas of immunology. Basic questions about the structure and function of the immune system at the molecular, cellular and physiological levels are asked in many different species. Clinical observations of immunodeficiencies and autoimmune diseases, in inflammations and allergies, help in the search for an explanmion, and eventually for a therapy, within a rapidly expanding understanding of the immune system. This increased knowledge encourages new strategies in transplantation and in the fight against bacterial, parasitic and viral infections as well as against cancer. New industries have developed which apply this knowledge in diagnosis and therapy.
From the first discussions in February, 1986 (see Box 1), the program committee (see Final Program of the Congress) decided that its main task was to assemble under one roof, in one program, these many different and often diverging interests in the immune system. In an attempt to bring together many scientists and clinicians with different training, introductory lectures at the beginning of each symposium are given by a chairperson who has been asked to summarize the current status of the field to be covered by the symposium. This should offer an immunologist not specializing in the given field an opportunity to update his/her knowledge of the recent dewlopments in this area. The work of many colleagues, and to a limited extent that of the chairperson introducing the symposium, should be covered. No other activities of the congress, such as workshops, are held concurrently with these introductions. Since the program includes 27 symposia, a; well as 130 workshops, this will allow every" tireless participant to hear 11 of the 27 introductions -a reasonable compromise considering the frustrating reality that it would take 80 days to participate in all events of the congress.
Th: program committee organized its search for topics, speakers Immunology Today, VoL 10, No. 8, 1989 Supplement Fig, 1 . Participation in the ~30 workshops of the congress is shown by the number of abstracts submitted (dotted bars). Based on the provisional program of the symposia and workshops, 140 national and international advisers to the program committee were asked to select the sessions that they would like to attend (closed bars). The horizontal axis indicates the works,5op number: on the top left side (low numbers) are workshops with more basic interests, and on the bottom right side (high numbers) are those with more clinica,' and applied interests. The solid dots below the bars show workshops that the advisers considered to be of clinical interest. (However, of the abstracts actually received, many more covered clinically related topics than the advisers to the congress had anticipated.)
Nevertheless, everyone realizes that, with the rapid advancements of modern immunological research, the program should provide some flexibility for the latest, hot news. Therefore, at least 30 minutes of each symposium have been kept open. The symposium chairpersons have been asked to suggest their latest additions to the program as late as possible, not earlier than four weeks before, and hopefully, only at the time when +he congress convenes in Berlin. The latest, hot additions will be specially announced on each day of the congress. Workshops often tend to be neglected. TEe program committee has tried to strengthen the role of the workshops within the total program as places not only for presentation of experimental results and ideas, but also for ~';cussion. Half of the allotted time, therefore, should be devoted to discussions. Furthermore, the workshop chairpersons have been encouraged actively to solicit participation in the workshops from colleagues whom they consider important in their field.
Immunology is a fast moving, exciting field of science. The oldest participant of the 7th International Immunology Today, Vol. 10, No. 8, 1989 Supplement .trod ch .-Congress, an honorary member of the Gesellschaft f(Jr Immunologie, Michael Heidelberger, was born when antibodies were discovered in Berlin. The youngest participant was not born when lymphocytes were discovered, when variable regions of antibodies were found, or when it was recognized that T and B lymphocytes had to collaborate to elicit an antibody response. The lunchtime sessions on the history of immunology will attempt to retrace some of these milestones in the discovery of the immune system. Also at lunchtime, four national societies will begin what the organizing committee hopes will be continued with other IUIS member societies in the future:~ the presentation of the activities of irr, munological research in Brazil, Hungary, the People's Republic of China and the USSR.
Even the most widely discussed program of the congress is likely to miss some important areas of the field, or must exclude in its process of selection promising talent and topics and even established investigators and fields. As chairman of the program committee, I sincerely apologize to all those who feel left out, not appreciated, undiscovered or forgotten. Some of the weaknesses were visible to the program committee even before the congress started: perhaps we could have attracted more scientists from the Eastern Bloc and from Third World countries -half of all the abstracts are submitted by scientists from the USA, West Germany, Japan and the UK; and only 7% of all symposium speakers and 16% of all workshop chairpersons are women.
One main aim of the program committee was to combine the interests of basic with those of clinical immunology. Will it work? The 5142 abstracts received for presentation at the congress, show, at least, ',hat both areas are strongly represented, if not well balanced -much to the surprise of most of the national and international advisers (see Fig. 1 ). The program committee hopes that all of the many interests in the immune system will truly meet in Berlin, that the congress will contribute with exciting new discoveries to a better understanding of the immune system, and that many contacts will be made for successful international co-operation in the future.
The Base! Institute for Immunology, funded and supported by F. Hoffmann-La Roche Ltd Co., Basel, Switzerland, has been the site of the Scientific Secretariat of the Congress. My heartfelt thanks go to Ms Leslie Nicklin who, as secretary of the program committee, has helped organize the planning meetings and has handled the correspondence with nearly 100 national and 200 international advisers (altogether more than 15 feet of files, letters and records), and is now preparing the 5142 abstracts and approximately 250 contributions to the symposia and lunchtime presentations for the final program. Debbie Middleton's meticulous work is also gratefully acknowledged. On behalf of the organizing committee and the program committee, I wish to thank the Senate of Berlin-West, tile German Research Council (DFG) and Boehringer Mannheim for their support of the meeting on "The Immune System in 1988" that was held in April 1988 at Schloss Elmau, FRG. Finally, I thank all my colleagues of the national and international advisory board for their co-operation, suggestions, criticisms and help in assembling the program.
The 'Geseiischaft for Immunologie' (GFI) was founded in 1967 by 19 investigators in Marburg. The founders decided against using the name 'German Society. of Immunology' so that they could include members from German speaking countries in mid-Europe other than the Federal Republic of Germany. The first board of officers consisted of N. Hilschmann, K. Rajewski, H.G. Schwick and O. Westphal. It is interesting that the International Union of Immunological Societies (IUlS) was founded only two years later and that two of our officers (Schwick and Hilschmann) were also among its founders. The opinion of th~ founding members of the GFI was that, as a branch of natural sciences, modern immunology needed an organization for its represe~tation as a pro- fessional group, and that the most important specific goals of the society should be the promotion of basic immunological research and support of the younger generation of scientists.
The first annual congr~ : of the GFI was held in 1969 in Freiburg and attracted 315 participants. Since then, the GFI has held its annual meetings in the fall and, in fact, this year, because of the World Congress, is the first exception to this tradition. The meeting has been held several times in Austria and Switzerland, and twice a joint meeting has been held with the French society, in Strasbourg. Five years ago the meeting of the Leucocyte Culture Conference (the first meeting of which was actually held prior to the first GFI conference) was established as an additional spring meeting of the so-(~) 1989, Elsevier Science Publishers Ltd, UK. 0167-4919189/$02.00 ciety, and it is particularly suitdbie as a forum for younger scientists to present their most recent data but has proven useful to all of us. 
-i unoiody in FI G
Immunology Today, Vol. 10, No. 8, 1989 Supplement Since its foundation, the GFI has had three presidents (Westphal, Rother and Kalden) and two treasurers (Schwick and Kirchner). Its complete bo_=rd consists of 12 officers (present composition shown in Table 1 ). At the time of writing the society has 973 members; the membership list is updated every second year and is currently being prepared for the 1989 issue. Together with the American, British, French and Japanese societies, the GFI is one of the five largest members of tUIS. The society has five honorary members (Table 2) , and the Avery-Landsteiner award is biannually presented to an outstanding immunologist regardless of nationality (Table 3 ). This is the major prize of the GFI, which is kindly sponsored by the Behringwerke, Marburg. An additional p; ize,
--
the Otto Westphal prize, is awarded every second year for an outstanding doctoral thesis.
The GFI is especially honoured to have been chosen to host the 7th International Congress of Immunology in Berlin and in accepting this honour, we are cognizant of our past and the terrible fate that many excellent scientists suffered at the hands of the Nazi regime. It was due to their toss that science, and immunology in particular, was slow to recover and grow in post-war Germany.
When the society was founded, only a handful of immunology research institutes existed in Germany. Among these it is probably fair to single out the Max-Planck-lnstitut in Freiburg (formerly headed by O. Westphal and the late H. Fischer). Many of the immunologists now active in Germany received their training in Freiburg. Many others went to outstanding research institutes abroad including Australia, Israel, Sweden, the UK and the USA. We are most grateful for the acceptance and the friendship we found, and for the scientific training we received in these countries.
Although there are many chairs of immunology at medical and science faculties, as we!l as other immuno- Clinical research in the Federal Republic of Germny.
Clemens Sorg and Joachim R. Kalden
Starting again in the early 1960s, it has taken more than twenty years to re-establish clinical research at university medical schools. At the moment, the Federal Republic of Germany has 27 medical faculties, comprising 1725 professors, assisted by a scientific staff of approximately 12600, who teach more than 12 000 students per annum. (In comparison, the UK trains 4000 and the USA 17 000 medical students per annum.) In addition to teaching, however, German professors at medical schools spend a consider-able part of their time on patient care, since the university hospitals are part of the general health care system and predominantly provide routine services to the community.
The training and education of medical students is not entirely satisfactory: during their studies, students are not exposed to research activities, either in the laboratory or in seminars, or in journal clubs. There is no mechanism at present to identify, encourage and train students showing particular scientific talents. A higher standard for doctoral (~ 1989 , Elsevier Science Publishers Lid, UK. 0167-4919/89/$02.00 theses and for Habilitatien (that is, the entry qualification for a later professorship) in the field of medicine also seems necessary. Such doctoral theses should perhaps be obligatory and have similar standards to those of the faculties of basic science.
With regard to immunology, most medical faculties offer courses and lectures in basic and clinical immunology but, since these subjects are not part of final examinations, only students with a particular interest in this area attend these courses. Efforts have repeatedly been made by the Gesellschaft for Immunologie to include basic and clinical immunology as part of the main teaching courses for medical studies, but so far they have been unsuccessful.
Once qualified, scientifically oriented young doctors face the problem that positions in university hospitals do not necessarily provide them with the freedom to perform research in addition to their clinical duties. This lack of opportunity to become actively involved in clinical research is well recognized and is one of the many reasons why young medical doctors seek further training abroad -particularly in the UK and the USA. A problem then arises when these doctors come home to 'nest' at German University hospitals To make further progress, the fundamental structure of the German universities needs to be analyzed. German university professors, including those at medical faculties, enjoy tenured positions from their first appointment; this makes it difficult to develop procedures for redistribution of resources according to efficiency and achievements. However, looking back at the development of clinical research in this country over the past twenty years, it can be seen that considerable progress has been made, mainly due to programs initiated and conducted by the major science organizations. The present situation should be maintained and further improved. All societies in Germaqy engaged in clinical research should continue to support the Wissenschaftsrat, the Forschungsgemeinschaft, the Max-Planck-Gesellschaft and the Bundesministerium flit Forschung und Technologie. This concerted effort will then further improve clinical science in our country. The Federal Republic of Germany (FRG) spends 3.8% of its gross national product on science 1. It is debated whether or not this is enough for a wealthy country with scarce natural resources but an impressive economic power. The total :ui,~ of money spent for basic science in the FRG in 1987 was calculated to be 7.8 x 101C DM (Ref. 1)-55% of which (4.3 x 10 lo DM) stems from fiscal and non-profit orientated in.~'~itutions ~.
Further reading
In this article, we will restrict discussion to the situation of immunology as a basic science in the FRG. 
Raising funds for basic science in the FR6 -no spedal deal for immunologists_

Manias £rmer
Clinical immunology is dealt with in a separate section.
It is clear that immunology in the FRG is far from being an established scientific subject in its own right. In the vast majority of German universities (and their medical schools) immunology is dealt with under headings such as microbiology, virology, oncology, genetics, molecular biology, experimental medicine, bio-chemistry or cell biology. While the number of chairs for subjects such as immunology, immunobiology and molecular immunology is slowly increasing, a degree in immunology can be obtained in only a few places. Although the spreading of immunology into these many fields is a terrific source of progress for our scientific endeavours, it renders any attempt to quantify the amount of ~) 1989, Elsevier Sdence Publishers Ltd, UK. 0167-4919/89/$02.00 $7
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Immunology Today, Vol. 10, No. 8, 1989 Supplement S8 money spent on immunology in the FRG impossible.
The need for funding-the structure of research institutions in the FRG
In order to understand the German system of funding research, one needs to understand the organization of the existing (and competing) research institutions in this country.
First, there are the universities. All German universities are run by the state. Within the framework of the federal organization of the FRG, basic science (universities) is the responsibility not of the federai government (in Bonn), but of the eleven States (gundesl~nder) and their state governments (in, for example, D(isseldorf, Munich, Stuttgart and Hannover). Thus, universities in the various states have slightly different organizational structures and certainly different financial problems. The universities provide their research institutes with personnel, buildings, basic equipment and instrumentation, and infrastructure, requiring heavy investment. Financing an internationally competitive immunological research group is clearly beyond the scope of any standard German university, however, and research in university groups needs additional funding.
Second, th~r~ k the Max-P!anck-Gesellschaft (MPG) and the Max-Planck-lnstituts. These focus on natural sciences including immunobiology, immunogenetics and immunochemistry. The principal source of MPG's money is the Federal Government. In contrast to the universkies, the MPG can provide funds to fully support the research of its groups. Full support is a relative term, however, and most immuno logical groups at Max-Planck-Instituts also apply for additional money.
Third, there are a number of special federal research centers (GroBforschungseinrichtungen), among them the German Cancer Research Center (DKFZ) in Heidelberg. Despite their academic freedom these centers have a broad but defined scientific topic to work on. These centers also have 'hard' money, but again, additional funding is sought.
Finally, there are exceptions from and mixtures of these three institutionalized concepts -for example, Max-Planck groups not solely financed by the MPG, or university institutes not in the university but associated with it.
The Deutsche Forschungsgemeinschaft (Dr, G)-the main agency funding basic research
The Deutsche Forschungsgemeinschaft (DFG, German Research Agency) in Bonn is an independent, federal institution. Its purpose is to fund all aspects of basic science in the FRG 2.3. The DFG has a total annual budget of 1.1 x 10 g DM (Refs I, 2). As part of the federal burden-sharing, the DFG expects the universities/MPG to provide all the previously described academic and other infrastructures.
The researcher/immunologist has three major routes to apply for DFG money. First, she/he may apply for an individual grant for an individual project (Normalverfahren). This may include personnel, instrumentation and running costs for scientific equipment. These grants run for one or two years and may be prolonged. The DFG spent 4.4 x 108 DM on this program last year, 1.6 x 108 DM of this on biomedical sciences. Second, a group of scientists working on a related subject but who are distributed around the country may get together and apply for a common, topic-oriented grant: called a Schwerpunkt, within which the members have their individual projects. One period of funding runs for two years. Last year the DFG spent 2.1 x i0 ~ DM on this program, 6.1 x 107 DM of this for biomedical science. Finally, an already existing, active research center such as a combination of research institutes within one university or town may establish a Sonderforschungsbereich (SFB, special collaborative grant) with a scientific heading to which all projects must be related. SFB grants are reviewed every three years. The SFB program has 3.2 × 108 DM, 1.2x 108 DM of which are for biomedically oriented SFBs.
In principle, the access to DFG money is mediated via the scientific standard of the applications only. The DFG developed a peer reviewing system, and the rejection rate of applications may reach 15-30%. On a statistical basis, only half of the money applied for is actually allotted to the applicant's project by the reviewers.
Other state and private institutions
The Federal Minister of Science and Technology (Bundesminister f[ir Forschung und Technologie, BMFT) finances applied science developing into technology. Since the borders between basic and applied science are sometimes questionable, a substantial amount of the BMFT money also goes into aspects of basic immunology.
The various states (Bundesl~nder) either by themselves or in conjunction with federal sources, also put up programs to foster research institutions. The form, extent, focus and duration of u~e~ ...... efforts are different in every case, since they are expected to solve different questions.
Finally, we should turn to the sector of private funds and foundations supporting basic science/ immunology. A number of foundations have joined into the Stifterverband for die Deutsche Wissenschaft, which coordinates private funding at various levels 4. Numerous foundations do not operate under this cover, however and it is not possible to list them all in this article. In general, the support by private sources is a special deal between the institution, the researcher and the foundation. Since these arrangements are tailor-made, the advantages of private funding are much greater than the actual amount of money spent may suggest.
This article contains a number of crude oversimplifications, and ends with a remark which may not be shared by all our colleagues around the country: that with good immunological science one may raise funds in the FRG. The national funding of basic science is open, critical, balanced and fair. This is verified by the fact that working on international (or European) money is the exception rather than the rule in the FRG.
Ig genes, moJe¢ules and
• cdI development The immunogiobulin gene alphabet Imwnogiobulin genes was first spelled across the border from Germany, in Basel, Switzerland, by Susumu Tonegawa and his colleagues: V (variable), J (joining) and C (constant) gene segments. Work from laboratories aii over the world siveiy. The reverse seems to be true contributed to this and to the rest of the alphabet-the D (diversity) and N (nucleotide insertion) elements.
The current state of research on immunoglobulin genes is described in numerous review articles and in two books, one in 1987 (Ref. 1) and one which is due to appear now2. This article will not be a comprehensive national review, but will mention the work of a few German laboratories that have contributed to the field recently.
The organization and various functional aspects of the mouse heavy chain locus have been studied in K. Rajewsky's department in Cologne. The mechanism of isotype switching is currently being studied My I~QUUIMLII allU '..gllUClyUt '3, l~- cently they investigated the interleukin 4 (IL-4)-induced transcription in the target switch region which seems to be a prerequisite of directed switch recombination s . Some time ago, R. Dildrop established a new classification of VH chain sequences" which agrees fairly well with the results of V. gene mapping. The latter topic is being studied by U. Krawinkel's group, now in Freiburg. By a combination of genetics and blot hybridization they contributed to the present picture of the VH lOCUS as being organized in overlapping clusters of the known gene families s. To my knowledge, no systematic gene cloning and chromosomal walking studies on the mouse heavy chain or K loci have been performed todate. Onlythe comparativelysimple ,~ locus that contributes 5% of the light chains has been studied exten-in the human system: little is known about the X locus while the elucidation of the heavy chain locus is well under way in at least two laboratories 6.7. Following the initial work by Bentley and Rabbitts 8, the K lOCUS has been studied by our group in Munich for the past few years.
Our work started with the K genes of the mouse: V-J joining and its reciprocal recombir'~tion products 9, allelic exclusion, somatic mutations, promoters and expression ~o and gradually ascended to the K genes of man. To date, we have cloned about 70 V~ genes and linked them in six contiguous segments; however many of the genes were pseudogenes. The total number of V~ genes and pseudogenes wiii probably be well under 100. The map of the locus as delineated by Institut for Physiologische Chemie der Universit, t, D-8 M(~nchen 2, FRG. Hans 6. Za u pulsed field gel eiectrophoresls covers about 2 megabases (Mb) ( Fig.  1 ). It can be predicted on the basis of the transcriptional polarities indicated in the map that different V genes rearrange to the ]-C gene region by different mechanisms: the two J proximal Vs by inversion, the subsequent ones by deletion; the V genes of the 0.85 Mb Notl fragment should be rearranged by inversion since the reciprocal recombination products are found in the genome.
A unique feature of the VK genes of man is the existence of numerous non-processed genes outside the locus, on the same chromosome ( Fig. 1 ) and on other chromosomes 12. We cloned about two dozen such VK orphans and found some to be rather divergent but most of them only slightly defective functional V~ genes. dose" --m Immunology Today, Vol. 10, No. 8, 1989Supplement Chromosomal translocations of the immunoglobulin loci to the myc oncogene region, for example, as found in Burkitt's lymphoma, have been studied for several years in G. Bornkamm's laboratory 13 and more recently also by M. Lipp and colleagues ~4. Our group concentrated on the detailed characterization of breakpoints within the K IOCLIS ls.
Immunoglobulin gene expression is a booming business worldwide. While mechanistic aspects are pursued mostly by molecular biologists, the immunologist's interest is in the production of functional antibodies or antibody fragments from specifically designed genes. The work of two groups should be mentioned in this context. A group at Penzberg (Boehringer Mannheim) started by cloning from a hybridoma and expressing the genes for an antibody against creatine kinase 16. Their main aim is to produce antibodies of diagnostic and therapeutic value. A. PIfJckthun's Group in Munich succeeded in producinq an 'antihndy' in E. coil that consists of just the variable domains but binds phosphorylcholine wc:l117. Their objective is largely mechanistic and concerns problems such as the folding and assembly of chains and ligand binding. The hypothesis that somatic mutation contributes to antibody diversity has been disputed by immunologists ~or a long time and on occasions bitterly. Strong support for the hypothesis came from early work of Weigert and cclleagues on the primary structure of murine kl chains 1. However, direct evidence for somatic mutation in antibody V regions required molecular biology techniques that allowed the comparison of the sequences of V regions carried in the germ line with those expressed by somatic cells (reviewed in Refs 2 and 3). An early case of localized somatic hypermutation was reported by Zachau's group in Munich, who compared the productively and non-productively rearranged VK genes of a myeloma to their germ line counterparts and found multiple somatic point mutations in both 4. The ~ame group has provided further examples of somatic mutation in VK genes in the course of their work on the VK gene cluster in humans (see Zachau's contribution in this issue).
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Somatic antibody mutants
Klaus Rajewsky immune response. The development of monoclonal antibodies s provided a means of addressing this problem. In 1981, the first sequences of V region genes expressed in murine antibodies isolated from different stages of the immune response were obtained and compared to the corresponding germ line genes; this included an experiment that we carried out in collaboration with Baltimore's group 6.7. The results showed that somatic antibody mutants are selected in the response to antigen. It soon became clear through studies in a variety of models (see Ref. 3 for review) that as a rule, primary responses consist of germ-lineencoded antibodies, whereas in secondary and hyperitnmune responses to T-cell-dependent antigens somatically mutated antibodies are expressed. These mutants arise through a special hypermutation mechanism which introduces point mutations into rearranged V region genes at a high rate -higher even than the rate of approximately 10 -s per base pair per generation as determired by Wabl et aL 8 in a pre-B-cell line. Gene conversion -identified as a major mechanism oF antibody diversification in the chicken 9may play some 1°,11, but not a major role in the generation of somatic antibody mutants in the mouse.
The analysis of the pattern of somatic mutation in clonally related B cells showed that the mutations are introduced in a stepwise manner in the course of clonal growth 12-14.
Somatic hypermutation does not necessarily accompany B-cell proliferation (we have not seen it, for example, in expanding Ly-1 + B-cell clones15), but seems restricted to a particular pathway of B-cell differentiation, namely the generation of antigen-driven, T-cell-dependent Bcell memory; there is evidence that the process of mutant generation is set in motion by immunization ~6-~7. Somatic antibody mutants are then selected into the compartment of memory B cells, and, as shown by
Berek et aL 18, clones of such cells may persist in the animal for a long time. Upon a second contact with antigen, the mutated cells are able to expand and terminally differentiate into plasma cells in the absence of somatic hypermutation, as we have shnwn by _=n.~_!ysis of clonally related cells isolated from an adoptive secondary response 19. However, it is possible that some cells again enter the pathway of somatic hypermutation following a secondary stimulus 2°. C. Berek, who now heads a research group at the Genetics Institute at the University of Cologne, attempts to clarify this matter and to determine the microenvironment in which hypermutation is induced -perhaps the germinal center (see Ref. 21) .
The accumulation of somatic mutations in the antibody response coincides with affinity maturationi.e. the selection of high affinity antibodies. There is direct evidence that the two processes are causally related (reviewed in Ref. 3) . Thus, in the case of the response to the hapten 4-hydroxy-3-nitro-phenylacetyl we found that a single mutation, repeatedly seen in the same position, contributed most of the affinity increase observed in the antibody population. The other mutations carried by the antibodies apparently accumulated as 'background noise' because of the high rate of somatic mutation 22,23. In contrast, in the response to a (more complex) protein drlEIgeFI, ~]lTIrll~y maturation occurs in a stepwise way, concomitant with the stepwise occurrence of somatic mutation in the course of clonal expa I!sion 24.
Thus, in a particular and critical pathway of acquired immunity (namely that of memory generation in the B-cell compartment) a new repertoire of antibodies is generated through a special mechanism of somatic hypermutation and cells expressing mutated antiboclies are selected as memory cells on the basis of their affinity for antigen. This process results in affinity maturation of the antibody response. It may also enable the immune system to cope with microbial mutant~ arising in the course of infection.
The physiological risk of somatic hypermutation lies in its potential to generate autoreactivity. Model experiments from our laboratory 2s,26 and by others (see Ref. 3 ) have shown that single point mutations can result in profound changes of antibody specificity, and there is also evidence that antigen binding loss mutants are generated after immunization 19. Mutants of this type may occasionally have acquired specificity for a self antigen 27 and produce autoimmune disease2S. The mechanism of somatic hypermutation and its (T-cell mediated?) control is thus a key issue for future research.
Ailelic exclusion development -one facet of B-call G. K hler
An important step in B-cell development is the assembly of spatially separated gene segments into contiguous immunoglobulin (Ig) heavy and light chain variable region (VH and VL) genes. First VH and then V, genes are rearranged and this leads to the sequential expression of H and L chains in pre-B cells. The regulation of the rearrangement process is an interesting area of B-cell research which is actively pursued in labora-
tories in Cologne and Freiburg. This short article discusses experiments covering this facet of B-cell development.
Two experimental systems have been used to study the regul3tion of rearrangement. First, the B-cell compartment of mice transgenic for fully rearranged H and L chain genes was analysed. Second, H and L chain genes were introduced into actively rearranging pre-B-cell lines and their effect on rearrangement was studied. The results of these studies are summarized in Fig. 1 .
Mice expressing transgenic I~ $11 ~ 1989, Elsevler Science Pubtishers Ltd, UK. 0167-491 /89/$02,00 .
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Immunology Today, Vol. 10, No. 8, 1989Supplement $12 heavy chains have fewer B cells, most of which express the transgene and only a few coexpress endogenous H chains 3-s. The lack of endogenous H chain expression is because the endogenous Ig H alleles remain unrearranged or in an immature D to JH joining configuration, supporting the hypothesis 6 of a negative feedback of the H chal.i on its own rearrangement (see negatively marked arrows in Fig. 1 ). Refinement came from experiments showing that only the membrane anchored I~ and not its secreted form (lacking the transmembrane region) exerted the negative feedback 7.s. It is debated whether the H chain alone, the H-L-chain combination or both are functional in the negative feedback inhibition (see broken arrows in Fig. 1 ). Arrest of endogenous VH gene rearrangement in transgenic mice may be due to an accelerating effect on B-cell differentiation. Since the trans-i~ is expressed earlier in ontogeny than endogenous I~ (Ref. (Refs 10,11). This line carries a DJH3 join on each Ig rl allele and continues to rearrange its VH lOCUS while growing in culture: 12 secondary D to JH4 and 19 Vto DJ rearrangements in 65 reclones were counted. When a construct coding for membrane I~ (with or without a k light chain) was introduced by DNA transfection techniques, only 2 D to JH and no VH to DJH joins were observed in 31 reclones analyzed which argues in favour of a direct negative effect of I~ in the VH-rearrangement process.
No VL-gene rearrangement was observed in these clones. However, in subclones carrying nonfunctional VD.IH rearrangements on both Ig H loci, expression of transfected membrane, but not secretory I~, led to the onset of '." rearrangements 11. It was concluded that in pre-B cells of a more mature phenotype, membrnne t • induces VL rearrangement ( Fig. 1 , positively marked arrow). Evidence for this came from transgenic mice in which the major B-cell population expressed transgenic H with endogenous L chains 4.7,12. This indicated that the transgenic H chain did not inhibit and may have induced L chain expression.
The first evidence of Ig-feedback regulation on rearrangement came from K transgenic mice ~3. In only those B cells expressing endogenous H chain together with the transgenic light chain was the expression of endogenous L chains suppressed. In these cases the endogenous VL lOCUS remained in the unrearranged germline configuration. It was concluded that the H-L chain combination, but neither chain alone inhibited further VL rearrangement ( Fig. 1 , negatively marked arrow).
To learn more about which domains of the ~ chain are required for its regulatory function and whether other Ig H chains were also effective, mice transgenic for the Ig 8 chain, were analysed. These mice showed a similar phenotype as l~ transgenic mice 14. Since the 8 chain lacks the domains homologous to C1~2 and C1~3, it was concluded that these domains could be dispensable for the regulatory effects. In contrast, expression in mice or in a pre-Bcell line of a p, gene lacking the first constant domain did not activate VL rearrangement (G. K6hler, unpublished). Light chains interact with the VH domain, and covalently with the C1~1 domain. They are necessary for the membrane deposition or secretion of I~. Presumably the light chain displaces the heavy chain from a protein (gp78) of the endoplasmic reticulum which binds to the first constant domain of heavy chains is. If, indeed, surface expression of heavy chains in pre-B cells is a prerequisite for their regulatory function, other proteins may also be required. This points to a role of genes specifically expressed in pre-B cells called Vpre-B (Ref. 16 ) and k5 (Ref. 17) . They are homologous to the variable (V pre-B) and the constant (X 5) region of the ~, light chain and their presumptive products are expressed in association with I~ chains on the surface of some pre-B-cell lines 18.19. In addition, genes (B29, MB-1) have recently been described, that are expressed in pre-B cells and B cells 2o,21. The product of one o. these genes (MB-1) is apparently associated with the membrane I~ chain and is necessary for its surface expression 22. Furthermore, an amino acid sequence motif has been identified in the cytoplasmic portion of B29 and MB-1, which is shared by proteins forming the Fce receptor and by members of the T3complex 23. The proteins of this complex are aFsociated with the T-cell receptor and are important for its surface expression. They may also be necessary for signal transduction during antigen activation. It is conceivable that a B3-complex, with similar functions, exists for the B-cell immunoglobulin receptor and that it also plays a role in regulating early B-cell differentiation.
During these studies other important discoveries have been made. The Immunology Today, VOI. i0, No. 6, 1969 bupplement V-replacement recombination into fully rearranged VH loci has been found, which increases H chain diversity and possibly decreases the number of nonfunctional rearrangements 24,25. The progression to X chain expression seen in a pre-B-cell line apparently depends on a prior recombination event involving downstream recombining sequences and resulting in deletion of both K alleles 26. Finally, evidence that suggests why alleSc exclusion must be tightly controlled has been put forward 4. Transgenic mice coexpressing trans-and endogenous Ig on the B-cell membrane are unable to respond to T-c~tl-independent antigens of the class II type, but do respond almost normally to helper Tcell-dependent antigens. Specific serum IgM of T-cell-dependent responses consisted of mixed molecules of endogenous and transgenic origin, whereas serum IgM of T-cell-independent responses did not show the transgenic component. Possibly only those rare cells that have lost the transgene expression were able to respond in a helper T-cell-independent fashion.
In Germany, research on murine histocompatibility (H-2) antigens shows a satisfying degree of polymorphism with each group working in this field going through '~:"-'-or ~'~; ......
I I III l~i
i I lUJ~l ~vIJiutionary changes. There are two main centers of H-2 research, T0bingen and Heidelberg, and many small groups distributed throughout the Federal Republic of Germany.
Recognizing the importance of this field, major histocompatibility complex (MHC) research was supported for six years by a special programme (Schwerpunkt) from the major German funding agency, the Deutsche Forschungsgemeinschaft. This support was extremely valuable and led to many interactions between the German laboratories involved. However, the latest philosophy of the Deutsche Forschungsgemeinschaft -that it i~ sufficient to teach a young bird to fly-means that funds are now going preferentially to 'new and innovative projects', unfortunately disregarding the fact that established fields can also When writing about MHC research in Germany one must mention first the illustrious and sometimes controversial figure of Jan Klein, who resides in the Max-Planck-lnstitut for Biology in Tnbingen, secluded in the pleasant mountains of the Schwabische AIb. Perhaps too secluded it is felt, with regret, by many of his German colleagues. He was one of the founders of tne rapidly expanding field of MHC research and has had a considerable impact on many of us from the days when he and Donald Shreftier proposed the two locus model of the H-2 =omplex in 1971 (Ref. 1). Jan Klein is a real scholar, who has given us important conceptual frameworks in MHC imrnunogenetics, and has always tried to bring order into the MHC and its nomenclature. Besides a vast number of papers, he has also written several important textbooks in which he does not hesitate to express his personal opinion, usually in a refreshing historical perspective. His Natural History of the MHC Complex 2 is excellent -delightful to read and an endless source of information. His witty and cutting commentaries in the 'Odd Page' of his journal Immunogenetics are also delightful to read. For example, his glossary entitled "They don't cite me ''3 expresses nicely the feelings and difficulties faced by most of the authors of this issue of Immunology Today who, in a limited space, are trying to present a fair picture of immunology in Germany.
MHC polymorphism
Jan Klein's major interest was, and is, the polymorphism and evolution of the MHC complex. In a study on wild mice captured all over the world, he and his group found that C~ 1989, Elsevier Science Publishers Ltd, UK. 0167--4919/89/$02L00 S13 F Immunology Today, Vol. 10, No. 8, 1989 Supp'ement S14 for each of the class I and class II loci there are 60 to 100 or more alleles. Until recently, all cases of polymorphism were thought to have arisen after speciation. However, in many papers Jan Klein has provided more and more conclusive evidence th3t MHC polymorphism pre-dated speciation 4. This novel hypothesis was voiced by him as early as 1980. Studying wild mice, Klein also observed a surprisingly high frequency of lethal or semilethal t haplotypes. He proposed that the various t chromosomes were derived from a single ancestral chromosome. Jan Klein is not someone who avoids controversies. When he and Zoltan Nagy observed that liposomes can stimulate class-ll-restricted T-cell clones, he proposed that antigen processing was not always necessary -a conclusion that is disputed by other investigators. During their studies on lactate dehydrogenase (LDH-B)-specific and I-E-restricted, suppressor T cells and suppressor factors, Klein and Nagy suddenly found themselves on 'an involuntary trip =s into the dubious world of I-J antigens which they had previously fervently erased from the H-2 map.
Another group studying MHC polymorphism is that of E. G~inther in G6ttingen. Using serology and cDNA cloning, GOnther investigated r~f IUI1-1~-6.7 t~nl~ nn= rl~¢c I ~nfln=n is known to act as a restriction molecule (RT1-A) for cytotoxic T lymphocyte (CTL) recognition. Next to the RT1-A locus are human leukocyte antigen (HI.A) DR-, DQ-and DP-like class II genes, class III (complement) and another class I cluster, probably harbouring Qa-like genes. The degree of potymorphism within the rat MHC appears to be much more limited than the H-2 complex, with only a dozen class ! alleles for RT1 -A locus and altogether about ten class II alleles. However, in contrast to the mouse, only a few wild rats have been investigated, and such studies could reveal a more extensive polymorphism. Since the rat is a good model for organ transplantation, these Jata are useful to groups studying the influence of various RT1 gene products on experimental organ transplantation.
While many immunologists feel obliged to do something useful, the laboratory of Klaus Rajewsky in Cologne is one of the strongholds of intellectual immunology. Although primarily involved in other fields, due to his wide interest in immunology, Rajewsky could not leave the MHC untouched. Using the first monoclonal anti-H-2 antibodies, which were produced in his laboratory by Lernke and Hammerling in 1977 (Ref. 8), B. Holtkamp and colleagues selected structural var!~nts of the H-2K k molecule 9. With W. Weichel, they showed that the respective epitopes could be mapped to the outside of those parts of the class I molecule that form the peptidebinding groove. These structural variations had little influence on Tcell recognition, thus confirming the view that antibodies and T cells see different epitopes on MHC molecules.
MHC: structure-function relationship
After GOnter J. H~mmerling~s move from Cologne to the German Cancer Research Center in Heidelberg, the latter developed into one of the major centers for MHC research. Most studies were aimed at understanding the relationship between structure and function. The epitopes recognized by a large panel of monoclonal, anti-H-2 antibodies were mapped and found to be different from those recognized by CTL. More precise information was gained from the class I exon shuffles n~n~r:fa~J ~/ [~rn~J Arn~l~J :n~J ~lln~ ing of research on one of the most intensively studied artefacts in immunology'.
Tumor expression of MHC antigens
Another major research area in Heidelberg is the role of MHC antigens on tumors. Many tumors in both rodents and humans have defective MHC class I expression. Hammerling's group observed that the restoration of class I expression by class I gene transfection led to the abrogation of tumor growth and metastasis in syngeneic mice 1 ~. Subsequent studies showed that the transfected class I molecule provided the H-2 restriction element required for the recognition of a tumor antigen by CTL While it is accepted that CTL require class-l-positive target cells in several systems, an inverse correlation between natural killer (NK) lysis and class I expression on the NK targets has been observed. In H-2 gene transfection studies, SturmhOfel and Hammerling showed that the expression of the class I antigens was directly responsible for the increased resistance to NK lysis. The importance of MHC antigens for ~tumor growth led to studies on the molecular regulation of MHC expression. U. Maschek has found that K and D genes can be silent because of changes in the chromatin st~uc- Kvist (the latter working at the EMBL). These early studies showed that the class I determinants seen by CTL were exclusively formed by the ~1 and a2 domains 1°, which is con-sist~,~t with the picture derived from Bj6rkman's crystallographic structure of the HLA-A2 molecule. However, the ~3 domain is also important because it is involved in the interaction between the Lyt- To test whether the lack of HLA expression on human tumors correlated with more metastasis and higher malignancy, a large number of human tumors were screened in many laboratories. In Heidelberg, Momburg, M611er, H~immerling and colleagues found deficient HLA expression in 30% of colorectal carcinoma specimens 1~. However, MHC I~,ad no influence on survival or relapses in a follow-up study. On the other hand, HLA-deficient human Bcell lymphomas fell predominantly into the inure malignant group.
MHC transgenics
Recently, many class I and class II transgenic mice have been produced Immunology Today, VoL 10, No. 8 l gR c} ~(~pplement in Heidelberg to study tolerance, immunity and MHC function. To investigate whether soluble MHC antigens could fulfill the function of membrane bound MHC, B. Arnold produced transgenic C57BU6 mice secreting soluble H-2K k into their serum t4. These mice were not tolerant to membrane bound K k because they could still make Kk-specific CTL and antibodies, possibly because soluble K k cannot efficiently crosslink receptors or interact with Lyt-2. In all textbooks, the HLA-C antigens are attributed with the same functions as HLA-A and HLA-B although no experimental data existed to support this assumption. Using HLA-Cw3 transgenic mice, Dill and colleagues ~5 first showed that HLA-C could indeed function as a transplantation antigen anc~ as an MHC restriction element. The HLA transgenic mice have proved to be extremely useful. Because they are tolerant of HD-~ framework determi-;,1ants, they are powerful tools for the production of monoclonal antibodies (mAbs) against polymorphic HLA determinants (G0nter H~mmerling in Heidelberg, and Ulrich Hammerling in New York, in collaboration with B. Dupont and S. Young, Sloan-Kettering institute, and S. Weissman and J. Chamberlain, Yale). This new technique may change the field of HLA typing by setting it cn a basis of standardized mAbs.
Qa region products
Peter Robinson (now in Harrow) spent many years in Heidelberg. As early as 1981 he wrote a cautionary note that the unexpected expression of 'alien' H-2 antigens on tumors is frequently best explained by a genetic impurity of the tumor cells or mice (a finding which was recently rediscovered for some UV-induced tumors). His main fields of interest were L32-microglobulin (132m) and Qa region products, ite described two allelic forms of 132m in inbred mice and found further alleles in wild mice. He also showed that 132m, which is associated with class I antigens on the cell surface, could be exchanged with exogenous 132m.
Since class I molecule_ ~ bind ~32m, Robinson used anti-~m antibodies for identification of new Qa region encoded products. He found a class I protein called Qb-1, which was found to be secreted by lymphoid cells 16. There are two pathways by which Qa antigens can be secreted 17. For example, Qa-2 is membrane bound via a glycosylphospholipid anchor and can therefore be processed to a soluble form. Qb-1 on the other hand, has an incomplete membrane-associating domain. The Qb-1 antigen is encoded by the Q4 gene, as found by gene transfer studies by Robinson and Weiss 18. Elisabeth Weiss (Munich) has analysed the organization and structure of the O.a region genes in the C57BL/6 mouse showing that the Q4 to Q9 genes possessed very similar structures. The corresponding region of the H-2 k haplotype contains only three genes: Q4, Q5 and QIO.
Class-!l-associated invariant chains
N. Koch (Heidelberg) worked on the class-II-associated invariant chain (li) which, in general, is co-expressed with class II and can be co-induced in vivo in various tissues, with IFN-~/ (Ref. 19) . Transfection studies showed that one gene gives rise to two proteins, li31 and li41, due to differential RNA splicing zo,zl. The li sequence exhibits some similarities with the transferrin receptor -such as a fatty acylated cysteine close to the transmemblane region -and a sequence motif which is important for the recycling of the transferrin receptor. This suggests that the li chain may also be recycled. In this context it is of interest that a recent mAb detects li on the surface of human B cells (C. Wraight, G. Moldenhauer, P. Mtiller and P. van En-derO. The membrane orientation of li is the opposite to that of class II, with the amino terminus in the lumen and the carboxy terminus on the outside. No cleavable leader sequence was found 22 that is characteristic of class II proteins. Dobberstein's group at the EMBL use the li chain in order to understand how such class II proteins are transported through the various cellular compartments. Since the li chain is found in the endosomal compartment, it is possible that it transports the class II antigens to this compartment, where the class II molecules could meet peptides of endocytosed and processed antigens. In fact, recent studies by Stockinger and Koch suggest that the presence of the li chain is necessary for efficient antigen presentation by class-IItransfected fibroblasts 23. If con-firmed, this would finally give a much sought function to the li molecule.
There are some exceptions to the rule of co-expression of class II and li. Konrad Reske (Mainz) observed that surface expression of class II could be induced with IFN-~/ on bone-marrow-derived macrophages. Although li mRNA was induced in these studies, no translation was observed 24. In the case of rat class iI molecules, Reske observed that the same class II molecule can occur in two allosteric conformations which can be differentiated with the Ox6 and Ox3 antibodies which could add to the functional polymorphism of class II antigens 25.
Suppressor T cells
During the last few years, work on antigen-specific suppressor T (Ts) cells has met with increasing scepticism. However, in MOnster, E. KOlsch and his group persevered with their work on Ts cells which can be induced with low doses of antigen 26.27. These Ts cells can be cloned and express an ~,13 T-cell receptor. Some Ts clones are restricted by I-A and others by I-E. Whereas mouse T cells in general do not express class II antigens, the Ts clones and also the Ts cells induced in the mouse clearly synthesize !-A and I-E antigens 27,z8. K61sch speculates that the Ts clones can present antigen to themselves via these class II molecules. However, class II ex-. pression does not seem to be a prerequisite for the suppressive activity because Ts hybridomas generated with such Ts cells did not express class II (Ref. 29 ).
These few examples illustrate that MHC research has developed well in Germany. They also show that MHC research is still very much alive and that many unresolved questions remain, providing an exciting challenge to immunologists and biologists.
Although the cradle of the genetics and funGion of the human leukocyte antigen (HLA) complex did not stand in the Federal Republic of Germany, there have been many German contributions to this field. The following brief account of these activities cannot, of course, be complete but reflects our own view of a particular subject.
In parallel with a number of scientists from the UK and the USA, our
HLA-genes and function Elisabeth H. Weiss and Andreas Ziegler z
associated diseases, such as narcolepsy, myasthenia gravis or cortical adrenal hyperplasia 2. They have found that linkage disequilibrium between the various alleles of the dif-group of protein biochenfists headed by N. Hilschmann at the Max-Planck-Institut for Experimentelle Medizin in G6ttingen. In a Herculean effort, they isolated, from hundreds of litres own the construction of a physical map of the HLA complex ( Fig. 1 ), by assign ing individual genes to large restriction enzyme-generated DNA fragments that have been separated by pulsed field electrophoresis (or related) techniques 1. We used mutants with induced deletions of HLA genes or even monosomy 6 for this, to minimize interpretative problems due to DNA polymorphisms. Our data show that the organization of different HLA haplotypes is apparently very similar.
Genotyping studies have been carried out by several groups to define disease-associated alleles. E. Albert and his colleagues (Immungenetisches Labor, Kinderpoliklinik, Universitat M0nchen) are involved in the study of HLA class II and class III gene polymorphisms in various HLA-groups have collaborated on ferent loci from DRA to DQA2 is so of culture fluid, enough HLA strong that class II five point (locus) haplotypes can be deduced from the phenotypes in nearly all cases. C. Rittner, P. Schneider and their coworkers (Institut for Rechtsmedizin, Universit~t Mainz) have a longstanding interest in complement genes, some of which are part of the HLA complex. Their description of a distant, rare restriction fragment length polymorphism (RFLP) which is invariably associated with the presence of the BF*F allele 3 supports the previously observed lack of recombination between BF and the C4 genes. The disease association of HLA-B27 with spondylarthropathies was first studied at the molecular level by G. Riethm011er, E. Weiss and colleagues (Institut for Immunologie, Universit~t M0nchen) with cosmid clones encompassing the HLA-B27 locus 4.
Contrary to the expectation of most HtA geneticists, the first nearly complete sequences of HLA class II and 13 chains were not provided by molecular biologists, but by a large homozygous cells to purify class II molecules in sufficient quantity for conventional protein sequer, cing 5.6.
HLA antigen expression studies strongly rely on the availability of monoclonal antibodies against polymorphic or common determinants on HLA surface molecules. Such reagents have been produced by several groups, in particular those of J. Johnson (Institut for Immunologie, Universit~t M0nchen: especially anticlass II reagents), E. Westphal (Abteilung Immunologie, Universit~t Kieh anti-class I alloreagents) and A. Ziegler (anti-class I, II (allo)reagents).
C. MOiler and her colleagues (Medizinische Klinik, Universit~t T0bingen) have carried out a very extensive immunohistological analysis of HLA class II molecules of the major lymphoid organs and a few other cell types 7. Their most interesting result is probably that HLA-DQ antigens are expressed in a much more restricted fashion than HI_A-DR and HLA-DP molecules. Differential regulation of class 11 gene expression who established HLA class-IIdeficient B-cell lines from patients with HLA class II deficiency. They showed that some cloned cell lines re-express certain types of class II antigens, but never DQ molecules 9. The controversial issue of HLA antigen expression on spermatozoa was addressed by several scientists from the University of TGbingen, who found that neither normal nor various types of pathological spermatozoa had detectable amounts of these molecules on their surfaces 1°. Finally, the HLA antigen expression by tumour cells has interested several German scientists. J. Johnson and her colleagues (MGnchen) have found that HLA-DR expression in progressing human melanoma is associated with metastatic spread and suggested that gammainterferon may play a role in regulation of genes leading to phenotypic changes in this disease 1~. In a recent collaborative effort also involving groups in Kiel and Marburg, F. Momburg and his co-workers (Institut fGr Pathologie, Universit~t Heidelberg) have analyzed several colon carcinomas and found not only complete loss of class I antigens in several cases, but aiso differential loss of HLA-A or HLA-B molecules from turnout ce!~s 12, usually of only one haploWpe.
G. H~mmerling and his group (Institut fGr Immunologie und Genetik, Deutsches Krebsforschungszentrum, Heidelberg) were the first in this country to obtain HLA class I transgenic mice. By introducing the HLA-Cw3 gene into C57Bt/6 mice, they demonstrated that the Cw3 molecule has immunological functions comparable to those of the HLA-A and HLA-B antigens ~3.
For several years, functional assays to clarify the rele of class II gene products have been used by G. Pawelec and his colleagues (Medizinische Klinik, Universitat T0bingen). They used class II antigen-specific monoclonal antibodies to block 517 o/ody " Immunology Today, Vol. 10, No. 8, 1989 Supplement stimulation of T-cell clones, and recently provided evidence for the existence of class II determinants (termed 'DY') which stimulate autoreactive CD4 ÷ T cells with suppressive activity ~4.
Finally, a number of groups in West Germany have studied the association of HLA alleles with particular diseases using classical serology. H. Grosse-Wilde (Institut for Immungenetik, Universit~tsklinikum, Essen) investigated the role of HLA antigens in patients with drug-induced pseudolupus ~s. They observed an increase in the frequency of HLA-DR4 and a decrease of DR3 in the patients as well as an association of acute lymphoblastic leukemia with the HLA-Cw7 antigen in a collaborative study with C. MQIler (T0bingen) ~s. In view of the presence of human homologues of murine major histocompatibility complex (MHC)-Iinked t complex genes, the finding of C. and G. MQIler-Eckhardt (Institut for Klinische Immunologie und Bluttransfusion, Uni-versit~t Giessen) of male segregation distortion in narcolepsy families may be of interest ~7. Equally puzzling is the finding of G. Rittner (Institut for Humangenetik, Universitat Bonn) and her colleagues who established an HLA-linked increased chromosomal breakage rate in systemic ~.11:~I u~)|~ IJI~LIEI IL~ -. rUl I. CI il IUI q~, ¢] strong association between herpes simplex virus-induced erythema mul-tiforme and HLA-DQw3 has been shown by R. Wank and his coworkers (Institut for Imrnunoiogie, Univers,t~t MQnchen) 19 . This appears to be the strongest association reported to date between a virus-induced disease and an HLA class II antigen.
We would finally like to mention the continuous support which basic and applied research in the HLA field has received over the recent years in West Germany. This financial support has mainly come from the Deutsche Forschungsgemeinschaft through local 'Sonderforschungsbereiche' (special research areas) as well as programmes like 'lmmunogenetics of the MHC' which have provided a very useful platform for interaction for all German scientists involved in MHC research. 
Rebirth of German complement research
The fathers of the present generation of complementologists are P. Klein The research environment, the scientific atmosphere, the personalities of the individuals mentioned above and their enthusiasm for complement research favoured the success of their proteges. Over the past two decades, several groups have concentrated their efforts on the biochemical characterization of the various complement components and as this issue is now largely settled, interest has shifted to the biological, clinical, molecular, genetic and pharmacological aspects. The receptors for complement fragments as links to the numerous cellular activities modulated by these peptides, are being intensively studied. 
Compleme.| research
Cla~ical pathway
Complement polymorphism
C. Rittner (Institute of Legal Medicine, Johannes Gutenberg University of Mainz) has contributed from the very beginning to the characterization of the genotypic basis of complement polymorphisms, their allotypic variations and human complement deficiencies. He is particularly interested in the human leukocyte antigen (HLA)-Iinked class III gene products (C2 and C4). He and P. Schneider focus on the genetic basis of C4 polymorphism and C4 deficiencies and on the biological role of C4A and C4B gene products and the susceptibility of individuals lacking them to autoimmune disorders. For more than a decade, G. Mauff from the Institute of Hygiene, Cologne, has contributed to the same field --particularly the genetic basis of C4, C2 and factor B polymorphisms.
D. Bitter-Suermann and his coworkers at the Institut f0r Medizinische Mikrobiologie, Medizinische Hochschule Hannover, also study genetic polymorphisms and complement deficiencies of C4, C2, C3 and C3a receptors in guinea pigs. E. B6ttger in Bitter-Suermann's group proposed a theory to explain how these deficiencies lead to an impaired humoral immune response to T-cell-dependent antigens and to humoral autoimmune reactions, based on an immunoregulatory function of C3 and its fragments. This group also studies the biological activities, structural requirements and receptors for the anaphylatoxic peptides C3a and C5a. The detailed description of a test system for these peptides using guinea-pig platelets (ATP-release), which is sensitive, stimulus-specific and reproducible (S. Meuer), stimulated research on receptors for C3a and its synthetic analogues (R. Gorardy), ELISAs for the peptides in plasma with monoclonal antibodies (A. Klos), an~ investigations on the role of peptides in the pathogenesis of acute respiratory distress syndrome (ARDS) in a guinea pig model (T. Hoffmann and J. K6hl).
Alternative pathway
In W. Vogt's lab. at the Max-Planck-lnstitut for Experimentelle Medizin, G6ttingen, I.V. Zabern analyzed functional and structural changes that can be induced in uncleaved C3 and C4 molecules by exposing them to amines, chaotropes or by repeated freezing and thawing. These studies contributed to the understanding of the activation of the alternative pathway by the C3b-like form of C3. Interest in the question of whether an altered C3 similar to their studies might be generated by xenobiotic agents and thus contribute to pathological complement-mediated effects in vivo led to the discove.,y of the conversion of C3 to C3b-like C3 by drugs, such as ionic iodinated contrast media, penicillins and sulfonamides. A comparison of the properties of cobra venom factor from the two species Naja naja and Naja haja revealed differences in C5 binding and usage.
V. Brade (Institut fL~r Klinische Mikrobiologie, Universit~t Erlangen) has worked on the alternative complement pathw-~ ~-formerly called the properdin system -since the 1970s. He characterized the role of factors B and D in the C3-and CSactivating (anaphylatoxin-forming) enzymes on zymosan. In studies with mouse and guinea pig rnacrophages and with liver synthesis and secretion of D, B and P in addition to C3, synthesis of single chain pro-C3 by liver cells and inactivation of C3aresulting from deavage of secreted $19
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Complement components in health and disease
O. G6tze and his co-workers at the Georg-August-Universit~t, G6ttingen, work on the evaluation of the role of complement in disease (for example in renal failure, sepsis and the adult respiratory distress syndrome) using ELISA procedures and monoclonal antibodies to plasma C3a, activated C3, C5a, factor D, Ba and Bb as weU as C6, C7 and SC5b-9.
They also study the role of complement and complement peptides in cellular regulation and in the modulation of the activation/differentiation of B cells and T cells, rnonocytes and granulocytes in health and disease. In addition, the expression of complement proteins in blood leukocytes and other cells is ~,~l,,~4.~,J L.. AL--~l_a_~.*__ _,1[ --IrAklA I~VC::IIUCIL~U Uy Clll~ UI=LI~I,,LIUII Ul IIIl~,l~l/'~ and in-vitro synthesis of the respective proteins. The expression of cytokines in response to complement peptides is currently being investigated using these methods. R. Buger (Robert Koch-lnstitut, Berlin) works on C3, mainly identifying the functionally relevant molecular sites and their interaction with other complement and membrane proteins. These in-vitro studies are complemented by studies in genetically C3-deficient guinea pigs.
Control factors and receptors
W. Vogt (Max-Planck-lnstitut for Experimentelle Medizin, GOttingen) began his complement research in the early 1960s. He recognized 'anaphylatoxin' as a cleavage peptide of a precursor plasma protein and was first to purify it, confirming Jensen's finding of a relation to C5. A cobra venom factor, (CVF) was recognized as an anaphylatoxinreleasing substance and was also purified. A heat-labile cofactor essential for the activity of CVF was discovered in serum, and later identified as factor B. The interaction of factors B, D and CVF or C3b was analyzed and it was established that factor D could be replaced by trypsin. The reason that C5 activat,on is restricted to surfaces and the role of C3b as a ligand for native C5 rendering it accessible to either convertase was also recognized. Recently, a non-enzymic mechanism of C5 activation was discovered -oxidation by OH radicals. This indicates a positive feedback in inflammation, since the radicals are products of complement-stimulated leukocytes. B. Damerau in Vogt's lab was the first to show that purified C3a and C5a-desArg induce platelet aggregation. The biological role of the aminoterminal region of C3a was described.
The IL~ UIULll~llll:~try and molecular genetics were analyzed, as was the 'receptor' for C3b on Herpes simplex virus. The regulator protein factor H was analyzed; three messenger RNAs were discovered and regulation of transcription in different cells is now being investigated.
C3 activation products and T-cell interaction
U. Hadding, B. FaBbender and W. D~ubener at the Institut f0r Medizinische Mikrobiologie und Virologie, Universitat D0sseldorf, study the interaction of C3 split products, particulariy C3b and C3d, with macrophages and T cells. They showed that C3b as well as C3a could trigger the metabolism of arachidonic acid, ~esulting in a decrease in the expression of IA antigens after C3b treatment of guinea pig macrophages that leads finally to a reduction of T-cell proliferation in antigen driven systems. They also found evi-dence that C3d is responsible for further inhibiting T-cell proliferation, by interfering not only with interleukin 2 (IL-2) but also with IL-3 and IL-4 function in vitro. They have postulated the presence of a CR2-1ike receptor on T cells.
CE-C9
Finally, within the complement cascade the components C6-C9, which form the lytic membrane attack comple~ C5b-C9, are the subject of research by three groups. At the Institut f~r Immunologie und Serologie, Universitat Heidelberg, K. Rother and his co-workers (M. Kirschfink, G. Zitow, G.M. H~nsch, E.W. Rauterberg and U. Rother) examine the mediators of immune inflammatory reactions and the development of better diagnostic tools to assess complement activation in vivo. To focus on two topics, G.M. H~nsch described a membrane (C8binding) protein that inhibits Cmediated lysis in homologous systems. In addition, she investigated the involvement of C5b-9 in the progress of acute and chronic inflammation by analyzing the response of cultured glomerular or synovial cells to C5b-9. ~ ....... Without going into too much detail of the 'complement landscape' in Germany, we hope that we have shown that complement research is an active and dynamic branch of immunology in our country.
Since the original discovery by A. Schimpl and E. Wecker (W(Jrzburg) that soluble factors (T-cell replacing factors) replaced T cells in vitro in
T-cell-dependent, B-cell anti-sheep red blood cell responses 1, the investigation of lymphokines (or more correctly cytokines) has made considerable progress in the Federal Republic of Germany. With the advent of T-cell cloning, refined cellular techniques, molecular biology, sophisticated biochemistry and monoclonal antibodies, the obscure mixture of factors in T-cell supernatants has turned into the reality of purified molecules. Today, iymphokines are a major tool in basic and applied immunological research and have begun to establish their place in clinical medicine. Thus, their role in growth, activation and differentiation of lymphoid and non-lymphoid cells is almost as diverse as the number of investigators and c!inicians using them daily in the laboratory and hospital. In this sense, many more laboratories in Germany than those directly cited here play an active part in lymphokine research on a broader scale. This overview of activities in this field of research in the Federal Republic of Germany mainly includes those whose primary research topic is 'lymphokines'. Here we describe some of these research activities, foliowing the current concept of activation of T cells-which are the main producers of lymphokines -and also discuss the effect of lymphokines on other cells.
Helper T cells are activated by direct contact with antigenpresenting cells and interleukin 1 (IL-1) and possibly other cytokines, including receptor-inducing factors (RIFs) secreted by these cells. IL-I binds to its receptor on helper T cells, is probably internalized, and initiates a number of effects that lead to Tcell growth and activation. Epitopes that are important for IL-1 activity as determined by monoclonal antibodies, the receptor for IL-1 and the process of IL-1 internalization and its intracellular effects are investigated 7Institute for Immunology and Genetics, Ger- 
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by the groups of H-D. Flad 2 (Borstel), K. Resch 3 (Hannover) and P. Krammer 4 (Heidelberg), respectively. RIFs were originally described by T. Diamantstein s (Berlin) and seem to be mostly macrophage products; these are now being investigated by H. Wagner and co-workers in UIm 6.
After these initial events, activated helper T cells secrete a number of lymphokines. These include IL-2 and IL-4, which a~ter binding to their respective receptors have autocrine or paracrine growth factor activity on T cells. These lymphokines and their receptors are the focus of interest of many groups: Wagner and co-workers (UIm) are investigating which T cells on a clonal level secrete these lymphokines7; Krammer and colleagues (Heidelberg) and Schimpl and colleagues (WOrzburg) 8, are studying the reguiatlon of IL-2 (Schimpl) and IL-4 (Krammer 9) gene expression and the relevant 5' DNA sequences (Serfling, WOrzburgl°) . The role of IL-4 and its receptor in autocrine growth stimulation of normal and malignant T cells is also being studied by Krammer (Heidelberg) 11. Sebald (WOrzburg) 12 has determined the epitopes on IL-2 that are important for IL-2 receptor binding, while T. Diamantstein in Berlin has greatly contributed to the characterization of the IL-2 receptor in mice and rats using monoclonal antibodies ~3,~4. He has shown that such antlbgdies can be used to abrogate Tcell Jctivity and growth in autoimmune diseases (type 1 diabetes in the rat) is and graft rejection 16. E. (.SFs, IFN-~ and TNF. These cytokines are the focus of interest in many laboratories of academic institutions and the biotechnology industry. H. Kirchner's group investigated the importance of endogenous interferons in viral diseases and was the first to show that TNF also has antiviral activity zB. D. M~nnel, V. Lehmann, and W. Dr0ge (Heide!berg) and K. Pfizenmeier, KrOnke and P. 5cheurich (G0ttingen) and their associates are investigating induction of TNF secretion from macrophages, autostimulatory activity of TNF, TNF resistance, TNF receptors, and signals induced after TNF binding and other aspects of this potent mediator 2s-3r Krammer's group has developed a neutralizing monoclonal antibody against murine lymphotoxin and TNF which allows these cytokines to be tested in invivo murine models 3z.
Lymphokines are expected to have a considerable impact on the understanding of the pathogenesis of diseases and on clinical therapy. Continuous stimulation of growth by autocrine growth favors ot malignant B cells, for example, may be an important feature of this malignancy (K-M. Debatin and P. Krammer, HeidelbergP 3. The hypothesis of autocrine growth stimulation may also be fruitfully extended to other malignant diseases in which autocrine loops are found. In clinical therapy in many centers, several lymphokines have entered a trial phase and some have moved from trial to routine. Various clinical investigators including Mertelsmann (Mainz) 34, Welte (Hannover) 35, Porzsolt (UIm) 36 and von Wussow (Hannover) 37 have shown that the transition from experimental knowledge to clinical usefulness can be quick. Reconstitution of patients with depressed bone marrow function can be induced by injection of CSFs, particularly granulocyte-macrophage-CSF. This therapy is now frequently used and has proved beneficial to many patients. It has decreased infections and shortened the hospital stay of patients, such as those with bone marrow transplants. Furthermore, interferon has beccme instrumental in the therapy of laryngeal papilloma, hairy cell leukemia and chronic myelogenous leukemia and is also used in Kaposi Sarcoma treatment. In addition, local co-injection of IL-2 with a hepatitis B vaccine led to anti-hepatitis B virus antibodies in otherwise immunodeficient patients (S. Meuer, Heidelberg) 3s. These examples, therefore, show that lymphokines will play an ever increasing role in research and clinical medicine.
Activation of resting T lymphocytes to proliferation and terminal differentiation is a multistep process involving synthesis of interleukin 2 (11.-2), the receptors for it, and the interaction of both. Effective synthesis of IL-2 requires IL-1, the receptors for which must also be expressed. The biology of the cytokines and their receptors is dealt with in a separate contribution: here only the signalling of those receptors tha~ initiate this chain of events will be discussed: the T-cell antigen receptor (TCR) composed of the Ti-CD3 complex and the CD2 glycoprotein.
TCR signal transduction
Owing to the diversity of the TCR and the complex nature of the appropriate antigen, early studies of T-cell triggering relied exclusively on models using mitogens such as plant lectins. Since the introduction of activating monoclonal antibodies (mAbs), the signalling of the TCR can be studied more directly. The most commonly used mitogens, phytohemagglutinin (PHA) or concanavalin A (ConA), activate T cells through components of the Ti-CD3 complex and thus can be used to probe this receptor in species where specific antibodies are lacking (.~or example, see Ref. !).
The first well defined cellular signalling system consists of cyclic nucleotides. Although many reports have been published on their role in lymphocyte activation, it now appears that neither cAMP nor cGMP are involved as second messengers in activated T lymphocytes, but they may for example exert regulatory functions in response to hormones 2.
Several receptors elicit cellular responses by breakdown of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diglyceride, by activating a PIP2-specific phospholipase C ('PI response' 
Cellular signalling in T lympho¢ es. __
stores, and after phosphorylation to IP4, by gating Ca 2+ channels of the plasma membrane. Diglycerides, together with Ca 2+, translocate the cytosolic protein kinase C (PKC) to the plasma membrane, and thereby activate the enzyme. The act;~ated PKC phosphorylates proteins involved in specific cell responses.
Binding of activating ligands to the Ti-CD3 complex induces a rapid PI response. Although the majority of phospholipase C in rabbit thymocytes is found in the cytoplasm, this key en~me can be clearly demonstrated in highly purified plasma membranes, which also contain the substrate PIP2; this is consistent with their role in signal generation 3. Inhibition of the PI response by cholera toxin (which specifically ADP ribosylates GTP binding proteins, linking receptors to effectors such as adenylate cyclase (G-proteins)) had suggested that the TCR is coupled to phospholipase C in T cells by a Gprotein. In a human cy,~otoxic T-cell clone which was permeabilized by Fleischer (UIm) showed that nonhydrolyzed GTP analogues induced granule exocytosis. This was strongly dependent on PKC, suggesting that the G-protein involved in this cell activation is localized in signalling steps proximal to phospholipase C (Ref. 4). More directly, H. Sommermeyer and co-workers (Hannover) showed that the same GTP analogues specifically activated the phospho!ipase C in isolated plasma membrane from rabbit thymocytes s.
Evideqce that this G-protein is linked to the TCR -and thus couples it to phospholipase C -again comes from experiments with permeabilized T-cell clones, in which modulation of the Ti-CD3 complex by mAbs led to a state of nonresponsiveness to stimulation by GTP analogues6; however responses by direct PKC activators, such as TPA, could still be elicited 7. This correlates with findings that treatment of the Jl i human =,~at T lymphoma cell line with cholera holotoxin led to a rapid and specific loss of the Ti-CD3 complex, whereas other membrane pro-1989, ElSevier Science Publishers Lid, UK. 0167~.9191891502.00
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teins were not affected (H. Sommermeyer et aL, submitted). The nature of this specific G-protein is not yet known, but in plasma membranes of human lymphocytes at least Gs, Gm Gi3 and Gz are present (H. Sornmermeyer and K. Resch, unpublished) .
The activation of phospholipase C constitutes signal branching giving rise to more than one second messenger, an elevation of cytosolic free Ca ~+ and formation of diglycerides, which activate PKC. Inhibition of cellular responses with (unfortunately rather nonselective) PKC inhibitors suggested that this enzyme is critical in T-cell activation.
That both Ca 2+ and PKC activation are required and sufficient for proliferation of T lymphocytes was shown elegantly in experiments using PKC-activating phorbol esters such as TPA in conjunction with Ca 2+ ionophores.
B. Manger (Erlangen) while working in Art Weiss' group, contributed significantly to this two signal model for T-celi proliferation 1.8. Tt-is approach mediated events could be successfully bypassed experimentally and, on the other hand, strongly supported the essential role of phospholipase C-dependent generation of diglycerides and IP3 in receptormediated physiological signalling. In contrast to the phorbol esters, however, the physiological diglycerides are short lived, and, hence PKC activation is also transient (less than 30 rain) and reversible. When membrane permeable diglycerides were used, instead of phorbol esters, only IL-2 receptor expression was observed, while IL-2 synthesis and subsequent proliferation were absent (see also Refs 1 and 8) . The latter could be induced by repeated addition of diglyceride, suggesti:lg (together with other evidence ~.8) that short-term activation of PKC suffices for IL-2 receptor e?,pression, but sustained activation is required for transcription of IL-2 message. M. Szamel, Hannover, provided experimental evidence for a mechanism operating physiologically. In human peripheral lymphocytes stimulated $23
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with Ca 2+ ionophores and shortlived diglycerides, incorporation of cis-polyunsaturated fatty acids such as linoleic acid or arachidonic acid into membrane phospholipids ted to a sustained activation and translocation of PKC. Those stimulated ceils produced large amounts of iL-2 and subsequently proliferated. When the lymphocytes were stimulated with mAbs against the Ti-CD3 complex, PKC activatkn proved to be biphasic. A transient first phase of activation, which until then was the only one observed, could be attributed to the PI response, and was followed by a second, sustained PKC activacion, which became apparent only after one hour of stimulation -putatively due to a substitution of membrane phospholipids with polyunsaturated fatty acids (M. Szamel et aL, submitted) .
Changes in the phospholipid fatty acid metabolism have previously been analyzed extensively in mitogen-stimulated lymphocytes. In the plasma membrane the deacylation-reacylation cycle was activated involving activation of phospholipase Az and lysophosphatid acyItransferase, through which saturated fatty acids were substituted by polyunsaturated ones. Increase in *~'^ content of ~ ....... " .... "-" It is thus proposed that this 'phospholipid polyLnsaturation' (PP) response constitutes the long sought for second signal system, which, in addition to the PI response, is coupled to the TCR0 and required for initiating IL-2 synthesis and proliferation.
T-cell activation via CD2
Besides direct triggering through the Ti-CD3 T-cell antigen-receptor complex ~2, T cells can he induced to proliferate and to differentiate functionally following binding of rnAbs to epitopes of the 50 kDa CD2 glycoprotein ~3. This molecule is expressed by the vast majority of T lineage cells. It was initially suggested tha~ this mode of T-cell triggering represents an alte-native pathway of T-cell activation. Whether, in fact, this CD2-related mechanism allows T cells to be activated in the absence of antigen receptor triggering, that is in a nonspecific fashion in vivo, is not yet known. Several authors have suggested an interdependency between CD3 and CD2, based on experiments with T-cell receptor deficient mutants of human tumor cell lines showing that analogous intracellular events occur following triggering of Ti-CD3 or CD2. • Other evidence, however, supports the independence of CD2mediated T-cell activation from a functional T-cell antigen-receptor complex. For example, human T lymphocytes have been cloned and expanded which express Ti-CD3 but not CD2 (Refs 14, 15 ). Conversely, a population of TCR-CD2 + cells has been identified and studied in detaiP 6.~7. The latter population is clearly suscep'ih!e *o activation via J~"l"~'l P. d ...... ~. r" ...... ~---. I..J~ fined by anti-CD16 rnAbs) contribute to triggering natural killer lymphocytes 18. In addition, circulating T lymphocytes in a patient with ataxia teleangiectasia ~9 are unresponsive to CD2-dependent stimuli, despite expression of a functional Ti-CD3 complex, the CD2 molecule, a~_~ normal in-vitro responses following activation via Ti-CD3.
In certain physiological and pathological conditions, these two pathways apparently segregate 2°. Moreover, despite normal surface expression of the two receptor systems, human intestinal lymphocytes barely respond to CD3 activation and, at the same time, are hyperreactive to CD2 triggering. The finding that these mucosa! T cells constitutively exoress low levels of PKC supports recent suggestions that these two pathways of T-cell a~ivation identified to date are apparently differentially regulated at the second messenger level (Pirzer et a/., submitted).
A most convincing piece of evi-dence in favour of a TCRindependent role of CD2-mediated T-cell activation was provided by analysing functional consequences of binding of CD2 to its natural ligands, LFA-3 and/or T11TS ( Refs 21, 22) . Both ligands, either in purir'r I produce a strong triggering signal to cells, which is selective for alternative pathway activation, These ligands interact with CD2 via two sites against which individual mAbs have been produced (termed anti-T111A and anti-T111B), TI I ~A is apparently the triggering site for LFA-3/TI ITS whereas, in contrast, the T111B site is a binding domain for the ph,,'siological ligands (LFA-3, T11TS) . Reagents that selectively b~ock the signal provided through CD2-LFA-3 have allowed the role of the CD2-mediated pathway of T-cell activation in physiological immune responses (for example to soluble antigens or alloantigens) to be studied. It was found that a considerable proportion of immune responses is apparently mediated through CD2. Given these results, it seems hardly surprising that some types of immunodeficiency are related to a failure to activate human T cells via CD2. The existence of lymphocytes ex-pf~.19 uuul Ti-CD3 clnu--~ CD2, which, however, cannot be triggered through CD2 (see above) suggest that additional molecules are required or involved in T-cell activation through the alternative pathway. This notion is formally supported by gene transfer experiments showing that transfection of CD2 genes in non-lymphoid cells is not r;uffic;ent for mediating signals such as calcium mobilization through this molecule. Such findings have prompted experiments to identify additional cell surface molecules that may be associated with CD2 in T-cell triggering. To ~his end, mAbs were produced and screened for their capacity to supplement a submitogenic signal mediated by antibodies directed a( CD2 in vitro. Such antibodies were recently found and shown to be reactive with molecules of the CD45 (leucocyte common antigen) family. Interestingly, cooperation between CD2 and CD45 is apparently restricted to the high molecular weight species of CD45, namely the subunits defined by monoclonal antibody 2H4 (Schraven et aL, 1989) .
immunology Today, VoL I0, No. 8, 1989 Supplement Only a subpopulation of the CD45 + cells (CD45RA +) responds to anti-CD2 and anti-CD45 monoclonal antibodies whereas the reciprocal population (CD45RO +) defined by monoclonal antibody UCHL-1 (CD45RO) does not. Moreover, mAb 2H4 (to CD45RA) itself is comitogenic with CD2 whereas mAb UCHL-1 is not. More impurtant, while amplifying CD2mediated immune responses, the same monoclonal antibodies do not affect T-ceU triggering through Ti-CD3. Thus, besides LFA-3-T11TS, activation of CD45 apparently mediates an additional signal for T-cell triggering through the alternative pathway. A physical association between CD2 and CD45 has been recently shown by co-precipitation of these molecules following their crosslinking on the T-cell surface (Schraven et aL, submitted) .
Thus the alternative pathway of T-cell activation, besides serving as an amplification mechanism in antigen-driven immune responses, may provide a means of rapid recruitment of local T cells before sufficient antigen-specific ceils have been generated. If this is the case, then one would expect to find more clinical immunodeficiencies associated with failure of CD2-mediated T-cell acti-ration. Conversely, hyperreactivity of the immune system could be attacked at the LFA-3-CD2 interaction site or at the level of CD45 molecules. Finally, CD2-mediated immune responses may play a pivotal role in local mucosal immunity.
The functions of T lymphocytes depend on their interactions with other cells. For example, cytotoxic T lymphocytes (CTL) lyse target cells expressing the antigen used for their activation, and helper T cells induce the proliferation of antibodyproducing ~ lymphocytes. To trigger antigen reactive T cells, cellular interactions with antigen-presenting cells (APC) are required. The function of clonally distributed T-cell rece~,~ tors (~1~ or ~/8 heterodimers) is to convey antigen specificity. Moreover, the function of genes encoded for by the major i fistocompalibility complex (MHC) is to focus antigen reactive T cells to the cell surface of other cells. MHC glycoproteins rAbt f~r Immunologie der Universit~t, ~^-" Eselsberg, UIm, FRG; 2Max-Planck-lnstitut f(Jr !mmunbiologie, ~Obeweg 51, 0-7800 Freiburg, FR6.
T-cell receptors and cellular interactions
Xemu Wag, r ] and lgaus Ei ma,r, z achieve this by using two apparently unrelated strategies. Fiist, irrespective of whether antigen processing leads to MHC class I or class II presentation, stretches of specific amino acid sequences (peptides) derived by degradation from complete protein antigens bind to MHC products and are disp',a)*ed on the cell surface. Second, monomorphic interactions of MHC gene products with other members of the immunoglobulin superfamily (CD4-MHC class II products, CDS-MHC class I products) increase the antigen-specific activation, presumably by providing additional positive signals. In this scenario, engagement of the T-cell © 1989, £1s:.~er Science Fublishers Ltd. UK. O167-4919/89/$02.00 receptor (TCR) represents the prime signal for T-cell activation, while it is *~'~,,~ run,ion of MHC gene products to 'display' processed antigen such that crosslinking -via !igandreceptor interaction -can occur. Accordingly, the functinna! separation into two classes of MHC recognition responses -CD4 T cells recognizing antigen bound to MHC clas, II mol-ecul~s, while CD8 T cells recognize antigen bound to MHC class I molecules -reflects the use of an amplification device operating s~condarily to TCR crosslinking.
After triggering via TCR cross!inking, antigen-specific T cells express receptors for hormone-like glycopro-$25
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reins produced by a vanety of activated cells of the hemopoietic lineage. For example, various interleukins serve as communication signals between lymphocytes and control their donal growth and maturation into effector cells. Although the effect of these lymphokines appears to be pleiotropic and very much dependent on the nature of the target cells, interleukin 2 (IL-2) primarily promotes T-cell growth, while IL-4 preferentially causes growth and maturation.
Several groups working in West Germany have contributed significantly to this conceptual framework. K. Eichmann and F. Emmerich (Freiburg) showed that it is the concomitant crosslinking of TCR and CDS/ED4 molecules which triggers resting, peripheral T cells to respond to the growth promoting effect of 11.-2 (Refs 1, 2). On the basis of more recent data they concluded that it is the spontaneous association of CD4/ CD8 molecules with crosslinked TCR which triggers T-cell activation. Interestingly, crosslinking of CD8 molecules to TCRs in intrathymically developing T cells causes immature CD4+CD8 + T cells to mature into single positive, mature T cells, suggesting a role for the CD4/CD8 structures in thymic repertoire selection.
T cells, and peripheral mechanisms leading to their specific unresponsiveness (tolerance). Of particular interest is the analysis and the interconnection of the IL-2-and IL-4mediated growth pathways, and the role of IL-6 in inducing cell cycle progression. Recently, it has ,,~,~'~, found that IL-4 and IL-2 act synergistically to convey resistance to the immunosuppressive effect of cyclosporin A to clonally developing CD8 T cells s.6. In human fetal liver and placenta, D. Kabelitz . They panels of '-'-2b-(trinitrophenol) TNP found that SE binds to monomorphic specific c~ L clones tO perform functional and structural analyses of their antigen receptors 3. Accordingly, in-~itro cultivated CTL lines quickly select for clones using characteristic TCR types (V=IO and Jt~2.6). These results suggest the existence of immunodominant TNP determinants (TNP conjugated peptides?) presented by stimulator cells. J.T. Epplen fformerly working in Freiburg and now with H. Weckerl~ it, Munich) has shifted his main interest from the analysis of T-cell receptor chain usages of H-2b-TNP specific CTL clones to that of myelin basic protein (MBP)-specific T cells, and to auto-rea~ive '-~-........ T cells found in human rheumatic synovia. This group analyses the T-cell receptor and I~ chains ofT ce]!s invo!ved in the elicitation and suppression of induced amigen specific autoimmunity in animal models 4, K. Heeo ,,'~d H. Wagner (Uhn) are studyim_ ' _ ;;enal requirements for the primary actuation of rnurine CD8 MHC class II gene products of APCs and simultaneously triggers a variety of cloned human T cells expressing either the CD4 or CD8 phenotype 8. This mode of T-cell activation also occurs with Mycoplasma arthritidis mitogens 9.
In Mainz, the groups of A.B. Reske-Kunz and E. ROde and their collaborators are involved in studies to define the signal requirements for T-cell activation. Using an MHC class II synthesizing T-cell clone as APC, they showed that presentation of nominal antigens triggered lymphokine production in responding T cells, yet failed to entail IL-2 receptor upregulation with concomitant T-cell proliferation lo. The as yet unidentified lymphokine(s) responsible for this effect are currently being characterized. In addition, Reske-Kunz's group have successfully transfected insulin reactive CD4-T cells with gene segments coding for CD4 to show that the transfectants exhibited not only in-creased antigen reactivity to insulin, but also gained reactivity to an unrelated antigen '.1. They also recently defined a CD8 + T-cell clone which apparently recognizes the protein ovalbumin in a H-2 b restricted fashion, in the absence of externally added accessory cells 12. Does this mean that clonally developing T cells can function as specialized APCs able to internalize antigen, and to process and present it together with MHC class I antigens?
T. Diamantstein (Berlin) studies the physiology of the receptor for IL-2 (IL-2R) and the possibility of inducing specific irnmunosuppression in vivo by inactivating lymphocytes using anti-lL-2R monoclonal antibodies. In several animal systems including models for graft-versus-host (GVH) reactions, autoirnmune thyroiditis and autoimmune diabetes in the rat, he and his associates showed that a combination of anti-lL-2R monoclonal antibodies plus cyclosporin A effectively prevented the development of signs of disease. Interestingly, this protocol ailowed detection of suppressor cells13014.
Although there is clear and compelling evidence that T cells can function as suppressor cells, very few groups have succeeded in defining suppressor T cells at the clonal level. Over the last few years E. K61sch (Monster) and his group have cloned antigen-specific suppressor T cells (Ts) and analyzed their functional abilitie~ both in vitro and in vivo. These Ts-cel! clones show exquisite antigen specificity and bear 'classical' TCR ~13 structures is. As such, these data represent a stronghold denying the currently fashionable criticism of the existence of suppressor T cells.
Experimental evidence obtained over the last few ,,ears led M. Z~l!er (Heidelberg) to suggest that it is the idiotypic-anti-idiotypic interconnection of cellular components which maintains the immune system in a steady state. Predictions of this concept are that self-tolerance cannot be due exclusively to clonal deletion of autoreactive clones, and that immunological reactions Lawa~'ds external stimuli require the establishment. ~f a new steady state rather than activation of single populations. With a model system of tolerance induced by free hapten, M. ZOller has accumulated experimental evidence supporting this concept 16. h, , , , unuiugy Tuddy, 'vb ; 10, ; '~. & 193g Supp, 'e, e, t A H.G. Thiele and his associates use the rat T-cell marker RT6 to study the ontogeny of T cells in the rat ~7. Unlike the mouse, T cells of aduit rats lose Thy-1 expression, but become RT6-positive. Recently, the use of an RT6.2-specific cDNA clone showed that the inability of diabetes-prone BB rats to generate RT6 ÷ T cells is due to a maturational block rather than to a defect of the corresponding gene. In addition, A. Hamann of this group studies the role of lymphocyte surface molecules (for example LFA-1) in lymphocyte migration and homing mechanisms 18.
In conclusion, we have briefly mentioned the work of a number of Ge;man sdontists researching T-cell receptors and cellular interactions. Many questions remain unanswered but there is confidence that the problems in collating data from different model systems are lessening.
In the late nineteenth and early twentieth century, German scientists particularly anatomists and pathologists -were most proiific in investigating cellular anatomy and pathology of v~rtebrate organisms. Not only did they describe a variety of cells such as the Langerhans cells of the skin (1868), the Kupffer cells of the liver (1899) and tle blood monocytes (Paul Ehrlich, 1881) but they also described in remarkable detail the kinetics of the inflammatory processes (J. yon Cohnheim, 1873). The observations that phagocytic cells are the most prominent cell types in host defense reactions induced Aschoff in 1924 to include all cell types that shared the ability to phagocytose and store into the so-called reticuloendotheliai system Inr-#-~ ~l~,r-j I .
The term "accessory' cell has only recently been introduced to describe all cells that are capable of co-operating in the induction and regulation of cellular and humoral immune responses. Current literature suggests that in ~ddition to ~na~.fuphages and dendritic cells, endo- 
IViacrophages and accessory cells of the immune system
lllellS Sor~ 1 and de,,Louise Lohaiu,.Ma , z tnelial cells may also function as accessory cells; that is, most of the cel! types of the RES also seem to share this property. Metchnikoff, Ehrlich and later Aschoff entertained the notion that phagocytic cells were intimately involved in immune rea~ions.
More recently at the Pathology Institute at the University of Kiel the study of the origin of the blood monoq/te has been resumed. Applying enzyme cytochemistry, Leder (1967) showed that blood monocytes and granulocytes share a cornmon differentiation pathway within the bone marrow. This observation was substantiated by Parwaresch and Radzun at the same institute, by analyzing antigen expression on monocytes/macrophage~ using monoclonal antibodies (mAbs) 1. With mAbs, it,is.possible to discriminate tl~e phagocytosing compartment of the n,onocyte/macrophage ~ystem from that of immune accessory cells -~. The latter are represented by the dendritic reticulum cells (follicular dendritic cells) as the access-ory cells for humoral immune responses 3 and the interdigitating reticulum cells, Langerhans cells, indeterminate dendritic cells and veiled cells as the accessory cells for cellular immune responses. Before this, Lennert had already distinguished nonphagocytosing reticulum cells respresented by dendritic reticulum cells of lymph node fo!licles (follicular dendritic cells), interdigitating re~icu;um cells of T _~ones, and tibroblastic reticulum cells f,aia phagocytosing reticulum cells (also called histiocytic reticulum cells) 4.
The Institute of Experimental Dermatology (M~nster) is entirely devoted to macrophage biology. C. Sorg and his collaborators work on the role of macrophages in inflammation and focus on the question of how circulating blood monocytes find their way to the inflammation site and differentiate into macrophages. Their work indudes projects on monocyte-endothelial interaction and the phenotypic dynamics of macrophages in the course of various inflamrTatorj ~) 1989, Elsevier Science Publishers Lid, UK. 0167-491g/89/$02.00
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--i~~H#l#~ i~ F~-*# I mmunol og. vToday, Vo,. 10, No. 8, , 989Suppl ement S28 processes. In particular, the role of the macrophage migration inhibitory factor (MIF) in the differentiation of monocytes to macrophages is stbdled, As a spin off, this work has led to the sequencing and cloning of the cystic fibrosis antigen, which was identified as a product of myelomonocytic cells and seems to interact with MIF in a way hitherto not fully understood s. Furthermore, a novel angiogenic factor produced by a subset of inflammatory macrophages has recently been described e. With a panel of mAbs to human tissue macrophages (developed at this institute) new insights have been gained into the function of macrophages in inflamed tissues. For example, E. BrOcker (M0nster) 7 showed the association of certain macrophage phenotypes with a poor prognosis in human malignant melanoma; this was confirmed by G. Heidl (MOnster) on gastric carcinoma.
~ospholipid metabolism
Another center of raacrophage biology started in Germany in the 1960s at the Max-Planck-lnstirut for Immunbiology (Freiburg), under the d~rection of Herbert Fischer. Together with P.G. Munder (Freiburg) he worked on the phospholiDid metabolism of macrophages and with M.L. Lohmann-Matthes described lymphokineactivated macrophages as cytotoxic effector cells.
Munder and co-workers (Freiburg) studied the interaction of adjuvants and macrophages, and found that immunological adjuvants cause a drastic change in the composition of phospholipids in the cellula~ membrane of phagocytes. An increase of the potentially cytotoxic lysophos-nh~tirlv rho in~ wa~ nh~prvpd Slowly metabolizable analogs were synthesized and were in turn found to activate normal resident macrophages, as measured by a highly increased phagocytic and anti-tumor cytotoxic capacity. E. F~_rbe-_=nd his group described phospholipase A2 as a key enzyme involved in the modulation of many macrophage functions 8. They showed that macrophage phospholipase A~_ selectively releases arachidonic acid from membrane phospholipids and thus controls the generation of prostaglandins and leukotrienes. This pathway is acti-vated by a directed translocation of ina~ive cytosolic phospholipase A2 to cellular membranes. D. Gemsa and his group (Marburg) were among the first to explore the biological role of arachidonic acid metabolism in macrophages. They established macrophages as a primary source of prostaglandins and in particular of prostaglandin E2 (PGE2) -a potent mediator of inflammation and immunosuppression 9. They also identified C3B and CSB/9 as potent stimulators of prostaglandin synthesis which demonstrates a close link between two major inflammatory systems (the complement and arachidonic acid cascades). In the field of cytokines, this group together with P. Krammer (Heidelbe,g) showed that gammainterferon (IFN-~) is not the only macrophage activating factor. It is apparent that cytokines and prostaglandins modulate each other's effect. This was recently demonstrated by studying synthesis of tumo-necrosis factor oe (TNF-(x), which could be stimulated by increased PGE2-dependent cyclic GMP, whereas cyclic AMP displayed suppressive effects m. Kaever and Resch (Hannover) are also involved in research on arachidonic acid metabolism. Their data suggest that ~rotein kinase C is centrally involved in the regulation of macrophage eicosanoid synthesis via a phospholipase C-mediated signal transduction pathway. Thereby the intracellular free calcium level determines the metabolic route of liberated arachidonic acid ~.
Several groups are interested in the interaction of macrophages and lipopolysaccharides (LPS). Schade and Rietschel (Borstel) studied the endotoxin-induced formation of arachidonic acid metaboEtes and showea that macrophages release both cyclooxygenase and lipoxygenase products ~2. H-D. Fled (Borstel) and his group study the structure-function relationship between LPS and its fragments and their capacity to induce and modulate the production of interleukin 1 (IL-1) and TNF by human monocytes.
Freudenberg and Galanos (Freiburg) advanced knowledge of the interaction of LPS and macrophages by showing that macrophages responsive to LPS play a central role in the induction of LPS lethality, and also ;n tolerance to the lethal activity of LPS for galactosamine-sensitized mice ~3.
Macrophage-lymphocyte interactions
At the Institute of Immunology (Mainz), A.B. Reske-Kunz, K. Reske, E. ROde a~d their collaborators mainly study the role of macrophages and other cell types (IA + T-cell =lones, IA-transfect~d L ceils) in antigen presentation. Macrophages derived from bone-marrow cultures supplemented with granutocyte-macrophage colony-stimulating factor (GM-CSF) were inducea by iFN-~/ and GM-CSF to maximum antigenpresenting capacity 14. Antigen processing is also studied using insulin and a number of its A-chain derivatives. All these antigens, including a 14 amino acid peptide, required processing for efficient presentation with no indication of an involvement of proteolysis. The processing of antigen but not the antigen-lA recognition was blocked by inhibition of N-glycosylation of proteins in antigen-presenting cells is.
The work of J. Knop (Mainz) centers around the question of which cells participate in the induction of allergic contact dermatitis. This work also includes the role of Langerhan~ cells and other dendritic cells in the induction of cellular immune reactions. W. Klinkert (W(~rzburg) and his group have isolated rat dendritic cells from various lymphatic tissues ~6. These Fc receptor-negative dendritic cells act as accessory cells in mitogen-driven responses and present soluble antigen (acetylcholine receptor) to antigen-specific cell lines. These dendritic cells originate frci n radio-sensitive precur~nrs in the bone marrow which ca differentiate in vitro in the presence of a growth factor from supernatants of concanavalin ~ ~Ce~A)-stimulat~d spleen cells.
H. Peters (G6ttingen) has shown that human peripheral blood monocytes can be converted in vitro into highly potent accessory cells for Tcell activation. Concomitantly, they downregu!ate ~pical monocyte/ macr~phage markers, such as Fc recept,)rs and nonspecific esterase, they express dendritic morphology and veils and may represent an ontogenetic link between monocytes and accessory, cells in tissues.
Another approach to the study of macrophage-lymphocyte interaction was taken by Hadding (Desseldorf), who introduced the toxin of Clostridium dificile as a substance acting on macrophages to stimulate T-cell proliferation ~7.
R. Andreesen and co-workers (Freiburg) study The functional and phenotypic changes that accompany the maturation of human macrophages from blood monocytes ~8. Or~e of their ai~n~ is tu generate autologous activatad macrophages in culture for re-infusion into cancer patients.
Macrophages as ¢ffector cells
M.L. Lohmann-Matthes' group (Hannover) defined a new type of tumoricidal and microbicidal effector cell as an immature nonadherent precursor cell of the macrophage lineage ~9. This cell type has been isolated fro:=,~*3one marrow, spleen and liver of normal animals. It can be recruited in large numbers to these organs or can perform strong proliferation in an organ-associated way. IL-2 is a potent activator of this cell type and endows it with strong natural killer (NK)-Iike activities. Baccarini (Hannover) described a p75 IL-2 receptor on these cells as the only receptor responsible for the interaction with IL-2 (Ref. 20) . Macrophage precursors are increased in number during inf~---~t~Jons or tumor diseases and represent an effector cell population which is easily manipulated.
Mannel and co-workers (Heideloerg) were the first to describe TNF as a product of activated macrophages, thus representing a cytoto~ic effector molecule of macrophages 2~. Recent evidence from this group shows that defined tumor cell membrane proteins can induce TNF productic~n in human monocytes. T. Decker (Hannover) first reported the existence of membrane-asseciated TNF as a lyric mechanism of cell-mediated macrophage cytotoxicity 22. 7iegler-Heitbrock (M(~nchen) showed that huma~~ monocytes kill the TNFsensitive target Wehi 164, both by r;leans of secreted TNF and also apparently by TNF-dependent cellmediated mechanisms 23. The role of macrophages in the development of type 1 diabetes is studied by H. Kolb ;n the field of neuroimmunology, the role of the nicotinic acetylcholine receptor and distinct antigenic epitopes in the pathogenesis of myasthenia gravis have been studied bv K. Toyka and his group 1.2. While studying the involvement of the thymus clone in the pathogenesis of myasthenia gravis, MOIler-Hermelink's group showed acetylcholine-receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors 3,4, supporting the notion that the thymus might be involved in pathogenic events leading to myasthenia gravis. Worldwide studies of the pathogenesis of myasthenia gravis, including its immunogenetics s, have now been started, to develop immunological therapeutic strategies to improve the present therapeutic regimes for this disease.
Immunohematolocjy research here has concentrated on the identi fication of platelet reactive antibodies 6 as w,II as on the definition of alloantigen systems on r,l=4"=i=te and their clinical relevance Institut und Poliklinik for K/in. Immunologie und Rheumatologi~, Universit~t Erlangen, Krankenhausstr. 12, D-8520 Erlangen, FRG.
Clinical autoimmunity_
for idiopathic thrombocytopenia 7.8. The involvement of cold agglutinins in the pathogenesis of autoimmune hemolytic anemias has been investigated by D. Roelcke et aL 9.
In the interesting field of the inter-aGion between the endocrine and the immune system, studies are in progress on the immunopathogenesis of type I diab~_~tes and its possible immunotherapy 1°, its serological markers 11 the description of proinsulin-specific autoantibodies 12, and finally data on the immunogenetics of type I diabetes 13. In other areas of endocrine disorders recent interesting experiments performed by Scriba et aL ~4 provide evidence that plasmid encoded proteins from enteropathogenic Yersinia might play a role in the onset of Graves' hypothyroidism.
Immunologically-mediated liver disease research has concentrated on the involvement of immunological reguL=-ting mech_=nisms with special emphasis on d~sease entities such as acute and chronic hepatitis and primary biliary cirrhosis (PBC). Immunohistological analyses of mononuclear cells infiltrating the liver as well as T-cell clones obtained from liver tissue an~ from peripheral blood showed that in areas of tissue destruction in chronic hepatitis B, Research oroarams in Erlangen, at the Max-Pianck Clinical Research Group, associated to the Institute for Clinical Immunology and Rheumatology, study the phenotypes of T cells and macrophages in the inflammatory synovium of patients with RA, the search for clonally expanded T cells in RA, and investigate the immune response to cartilage antigens and to related microbial antigens 30.31. In the same center, studies are underway to look for the interaction of cells of the immune system with chondrocytes -characterizing antigenic determinants on chrondrocytes including the establishment of T-cell clones specific for chrondrocyte membrane antigens. These studies also include the evaluation of cytokines in activating mechanisms of rnesenchymal cells of the inflammatory altered synovial membrane. Experiments to modulate cell surface antigens of the mononuclear phagocytic system by different cytokines are in progress. Finally, T-cell clones obtained from the inflamed synovial membrane of RA patients will be analyzed with regard to their possible antigen specificity using a 150 kDa protein obtained from the synovial fluid of RA patients 32-34.
Studies on the pathogenesis of reactive arthritides are being conducted by Bitter-Suermann in Hannover, Heesemann in Hamburg, as well as in Erlangen and Munich 3s, with a view to gaining insight into the pathogenic mechanisms leading to RA. Ongoing research activities with regard to clinical autoimmunity in rheumatic diseases also include new approaches to therapy. Thus, in various centers, for exampie Heidelberg, Erlangen and Munich, in cooperation with Basle, a treatment schedule has been started using anti-CD4 antibodies in the treatment of patients with RA refractory to the traditional therapeutic regimes. Also in RA, as in other chronic connective tissue d~seases, treatment attempts have been started by using different cytokines such as gamma-interferon, for RA as well as for patients suffering from systemic progressive sclerosis.
Coming back to research on SLE, two lines of activities ar~ obviou_c: first, experiments with regard to the etiopathogenesis of SLE and, second, research on the molecular biology and the antigen cloning of nuclear and cytoplasmic antigens serving as target antigens in different connective tissue diseases, besides SLE.
Addressing the problem of the oligo-or monoclonal origin of anti-dsDNA antibodies, research in Erlangen showed that antibodies against dsDNA in SLE patients are of oligoclonal origin 37 and, furthermore, that a patient-specific antinuclear antibody pattern is present 38. New data also suggest that retroviral structures might possibly be involved in the pathogenesis of SLE. Studies conducted by Krapf et al. support the idea of retroviral involvement in the triggering events leading to SLE 39.40.
Further research activities, for example by Luermann, concentrate on the cloning and sequencing of U1 RNPs, this antigen is also considered important as a target antigen in SLE. Experiments on antigen cloning in other chronic rheumatic diseases such as Wegener's granulomatosis, juvenile RA, polymyositis, and progressive scleroderma, as well as overlap syndromes 41-4s are also in progress.
It should also be stressed that several institutions in the Federal Republic are involved in the international Standardization Efforts for Reference Material for the Demonstration of Autoantibodies. Thus, reference material was obtained for different autoantibodi~s against nuclear antigens 46, islet cell 47 and acetyl receptor antibodies 48, Finally, data were obtained recently regarding dilated cardiomyopathy suggesting that at least part of this disease is due to an autoimmune reaction 49.
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It is widely believed that insulindependent diabetes mellitus (IDDM) in humans is a sequela of chronic pernicio-s a,-toimm-ne r-aactiot,s re= suiting in progTessive destruction of cells of tL. = pancreatic Langerhans islets. Hypothet~Eaily, in genetically susceptible individuals as yet undefined factors could initiate immunological reactions antedating loss of ~ ce!ls. Aberrant expression of major histocompatibility complex (MHC) class II molecules on 13 cells has been proposed by Gian Franco Bottazzo and his colleague s , (London) to permit presentation ot I~-cell-specifr antigens for autoimmune recognition as the initiating event. However, a direct autoimmune attack ~n ~ cells has still to be unequivocally proven.
There are three animal models that can be used to elucidate the effector mechanisms of gradual 13 cell destruction associated with metabolic and immunological characteristics corresponding to Clinical Department, Dbbetes Research Institute, Auf'm Henneka,..p 6~., 0-4000 DO~el. doff I, FRG, immunology and dlabetes-on the search for triggers and eff ors_ Help Gleich ann those of IDDM in humans. These are first, the spontaneously developing diabetic syndromes of the BB (Bio-Breeding) rat; second, the NOD (Non Obese Diabetic) mouse and third, the form chemically-induced by multiple injections of streptozotocin (STZ) -an N-nitroso derivative of D-g~ucosamine, in susceptible mouse strains. There is general worldwide agreement that T cells are involved in the pathogenesis of diabetes in all three models and that histologically there is insulitis0 i.e. infiltrates of mononuclear cells at peri-islet and intra-is!e~ sites. Again, evidence for a direct autoimmune attack of unaltered rodent 13 cells still has to be shown. At the Diabetes Research Institute at the Heinrich-Heine-University of D(~sseldorf. investigators are exploring the mechanism(s) underlying the immune reactions involved in diabetes development in animal models. Helga Gleichmann and her associates analyse the specificity and significance of immune rea:ions involved in ~-cell-destructive processes and the initial site of action of STZ. They showed that T cells can be specifically stimulated by STZ. This was shown by means of the pop',iteal lymph node (PLN) assay. A T-ceildependent primary immune response towards STZ could be induced and specific secondary PLN responses developeci in SI-Z-primed recipients. In adoptive transfer experiments, S1Z-sensitized splenic T cells were detected. More recently, Christiane Klinkhammer found that STZ can readily induce transient Tcell-dependent MHC class II antigen expression in cells of multiple organs including tha pancreas. Pancreatic In cooperation with Bernard Green at the Hebrew University in ,~,usak. we are comparing a P-mber of newly synthesized STZ analogues with respect to their diabetogenicity and immunogenicity.
Hubert Kolb and his group are studying the role of macrophages in the disease process of BB rats and STZ-induced hyperglycemia in mice. In both models, ultrastructural studies demonstrated discrete intra-Islet iniiltration by macrophages preceding diabetes manifestation (Victoria Kolb-Bachofen). Administration of silica, which can inhibit macrophage activity almost completely prevented disease development in these animal models. Accordingly, macrophages were assigned an essentia! roie in the early phase of the disease process. They suggested that prevalence of macrophages able to engulf islet cells in the prediabetic phase indicates their cytotoxic activity towards 13 cells. Currently, they are analysing mechanism(s) of macrophage-mediated islet cell lysis in vitro. Their data on the preventive effect of T-ceU depletion and/or inactivation on diabetes development in IDDM animal models are in agreement with those reported by other laboratories. In addition, the effect of various immunemodulating compounds on the disease process is under investigation, with a view to designing a thera-S34 peutic regimen applicable in clinical trials. Thomas Linn and Konrad Federhn at the Clinical Department of the Justus Liebig University of Giel3en are also engaged in defining the sequence of events leading to 13-cell destruction in the STZ model. They found an STZ-induced prevalence of intra-islet macrophages at early disease stages, and increased MHC class ~1 antigen expression on infiltrating mononuclear cells, but not on 13 cells. Another aspect of their research is to abrogate the ~-celldestructive process by dietary compounds such as co-3 polyunsaturated fatty acids.
George K6hler and his colleagues at the Max-Planck-lnstitute for Immunology in Freiburg are studying the mode of tolerance versus autoaggression towards 13 cells by using transgenic mice. Their first data indicate that MHC class II antigen ex-~:ession on ~ cells results in loss of insulin secretion. Signs of lymphocyte activation, however, were not obtained. These results are in agreement with those of Sarvetnick et aL (San Francisco) and Lo et aL (Philadelphia). Expression of MHC class II antigens was directed by linking the respective DNA sequences to the rat insulin promoter. Presumabl.y, the pathogenesis of diabetes in these transgenic mice is not immunological in nature.
T. Diamantstein and his coworkers at the rmmunology Re-st=arch Unit of the Free University of Berlin with Hans J~rgen Hahn from Karl=" arg, GDR, are focussing on ab;:;:.3ation of 13-cell destruction in BB nts by transient treatment with immunesuppressive agents. This goal has been achieved with corn-, bined therapy of the anti-lL-2 receptor mAb, ART 18 and a subtherapeutic dose of %,c!osporin A. This regimen resulted in prolonged euglycemia in BB rats when given immediately after diabetes manifestation and in survival of allo~enic 13-cell gra#.s in LEW.lW rats rendered diabetic by streptozotocin. Currently, they are analysing whether this effect is due to elimination of reactive T lymphocytes only or if a state of tolerance has been induced as well. Their studies could lead to development of intervention and/or substitution therapy for patients with diabetes. When several B. burgdorferi strains were analysed by physicochemical and immunological methods, antigenic differences were seen between European and North Ameri-Various facets of cell-mediated immunity to bacterial and fungal infections are the major focus of S.H.E. Kaufmann's group in UIm. The activation of antibacterial and antifungal macrophage effector mechanisms by interleukins is being studied using murine bone-marrow-derived macrophages as a defined cell population (summarized in Ref. 22) . They have shown that in addition to interleukin-producing CD4 + T cells, CD8 + T cells with cytolytic activity are also involved in protection against intracellular bacteria (reviewed in Ref. 23 ). These findings !ed to the concept that cytolytic CD8 + T cells may contribute to host resistance by releasing bacteria from their niches within host cells that are unable to destroy their intracellular parasites. In this way, more potent phagocytes could eliminate the pathogens. At the same time, lysis of host cells by CD8 + T cells could be detrimental to the host since it allows microbial dissemination and leads to tissue destruction. Another Immunology Today, VoL 10, No. 8, 1989Supplement f t resproject of this group is the characterization of mycobacterial T-cell anti-9ens of potential value for vaccine design against leprosy and tuberculosis. One of the major T-cell antigens, the 65 kDa protein, is a heat shock protein which is highly conserved (for summary see Ref. 24 ). T cells specific for this molecule recognize epitopes shared by various microbes, and could therefore participate in cross-immunity to different pathogens 2s. On the other hand, some T cells are directed to epitopes shared by the bacterial and human 65 kDa protein, and could be responsible for certain autoimmune sequelae of bacterial infections (reviewed in Ref. 25) .
